Small molecules with high tumoral retention through intratumoral-injecting devices for the treatment of tumors

WO2026187947A4PCT designated stage Publication Date: 2026-11-19AYALA OROZCO CICERON
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/017764
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-03-04
Filing Date
2026-03-04
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing anticancer drugs face issues with poor pharmacokinetics, rapid clearance from the body, and limited tumor accumulation due to size limitations and carrier competition, leading to discontinuation in drug development despite potential therapeutic potency.

Method used

The use of small molecules with unique chemical and physical properties for intratumoral administration, optimized through controlled delivery using medical devices to enhance tumor retention and minimize systemic toxicity, employing methods such as apoptosis, necrosis, and immunogenic cell death.

Benefits of technology

Achieves total or partial tumor elimination with minimized secondary toxicity effects on healthy tissues by ensuring high retention and controlled release of compounds within tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026017764_19112026_PF_FP_ABST
    Figure US2026017764_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to methods that utilize novel small molecules or therapeutic compounds alongside medical devices to treat tumors locally. This approach involves controlled intratumoral administration of the therapeutic compound which has unique chemical and physical properties allowing high therapeutic potency and the molecule selectively retained in the tumor, which achieves total or partial elimination of tumors in subjects with cancer.
Need to check novelty before this filing date? Find Prior Art

Description

SMALL MOLECULES WITH HIGH TUMORAL RETENTION THROUGH INTRATUMORAL-INJECTING DEVICES FOR THE TREATMENT OF TUMORSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional application Serial No. 63 / 766,459, filed on March 4, 2025, which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION

[0002] The present disclosure is related to new methods using therapeutic compounds, medical devices, and methods for the treatment of tumors.BACKGROUND OF THE INVENTION

[0003] Most pharmaceutical industry and academic translational research laboratories strongly focus on developing anticancer drugs that are cancer-cell-selective, targeted to cancer cell receptors through the addition of recognition elements, appropriately distributed in experimentation subjects (biodistributed in the body to reach tumors efficiently), effectively cleared / excreted from the body, and most importantly, potent and safe. Having these common objectives in mind, Lipinski’s rule of five is a very popular predictor that researchers use as guidance to develop therapeutic molecules. Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to determine if a chemical compound with a certain pharmacological activity has chemical properties and physical properties that would likely make it an orally active drug in humans (Lipinski et al., 2001). The rule describes molecular properties as predictors for a drug's absorption or permeation, distribution or diffusion, metabolism, and excretion through cells and organs. Lipinski's rule states that in order to be efficiently internalized within cells by diffusion, a molecule must have no more than one violation of the following criteria: 1) No more than 5 hydrogen bond donors, 2) No more than 10 hydrogen bond acceptors, 3) A molecular mass of no more than 500 daltons, and 4) An octanol-water partition coefficient that does not exceed 5. There are computational tools that calculate these criteria for a molecule; for example molinspiration: www.molinspiration.com / cgi-bin / properties.

[0004] In this context, intensive research efforts can be spent on optimizing the therapeutic potency of compounds on cancer cells. However, the therapeutic potency and usability of thesecompounds in cancer cells are not always guaranteed for the treatment of tumors due to issues with safety (toxicity in vivo), pharmacodynamics, and pharmacokinetics profde in human patients or animals. Many potent drugs intensively investigated on cancer cells in laboratory culture dishes are later discharged or discontinued in the drug development process due to issues with poor pharmacokinetics and pharmacodynamics profiles. Many of these drugs have limited circulation in the bloodstream and are quickly retained in the liver and / or other organs, resulting in nearly null accumulation in the tumor. Sometimes these drugs are formulated through combination with a carrier (a noncovalent conjugate with a second molecule) to improve their pharmacokinetics profile resulting in limited or partial success, since the carrier also can compete for binding to the therapeutic molecule. Sometimes the carriers are too large in size which limits the crossing of biological barriers. To overcome these issues, this invention focuses on treating tumors, rather than cancer cells, and discloses small molecules and methods for treating tumors effectively. The invention focuses on using small molecules without the need to use a carrier (a second compound that is used to produce a noncovalent conjugate, a formulation). This disclosure provides methods for using molecules that are highly retained in the tumors for the effective treatment of tumors. These molecules could violate Lipinski’s rule and have poor pharmacokinetics profdes. In this particular way, a disqualifying property that was or could be used to discontinue a molecule in the drug development process now can be used as an advantage as it is disclosed in this invention for treating cancer.SUMMARY OF THE INVENTION

[0005] As provided herein, the present disclosure relates to methods that utilize novel small molecules or therapeutic compounds alongside medical devices to treat tumors locally. This approach involves controlled and engineered intratumoral administration of the therapeutic compound which has unique chemical and physical properties allowing high therapeutic potency and the molecule selectively retained in the tumor, which achieves total or partial elimination of tumors in subjects with cancer (e.g., the subjects can be human patients, laboratory rodents, and domestic or livestock animals). The mechanism of action of the compound for causing tumor elimination could include, but is not limited to, apoptosis, necrosis, autophagy, necroptosis, pyroptosis, ferroptosis, and immunogenic cell death, among others. In this context, the activationof immune system signals could lead to the abscopal effect (elimination of tumors at distant sites from the original treatment by immune system activation).

[0006] In some embodiments, the present disclosure provides methods of eliminating tumors in subjects or patients with cancer comprising:A) Contacting the tumor with a small molecule or compound, wherein the molecule or compound having unique chemical and physical properties is capable of being selectively retained in the tumor; AndB) Administering the compound locally in the tumor through a medical device, wherein the molecule or compound is released or delivered intratumorally under controlled and optimized conditions of dose, flow rate, volume, and fluid pressure; AndC) wherein the compound is capable of causing total or partial tumor elimination and minimizes secondary toxicity effects on healthy tissues.

[0007] In some embodiments, the present disclosure provides the use of a compound for eliminating a tumor comprising:A) Contacting the tumor with a small molecule or compound, wherein the molecule or compound having unique chemical and physical properties is capable of being totally or partially selectively retained in the tumor; AndB) Administering the compound locally in the tumor through a medical device, wherein the molecule or compound is released or delivered intratumorally under controlled and optimized conditions of dose, flow rate, volume, and fluid pressure; AndC) wherein the compound is capable of causing total or partial tumor elimination and minimizes secondary toxicity effects on healthy tissues.

[0008] In another aspect, the present disclosure provides a composition for use in eliminating a tumor in subjects comprising a compound, wherein the compound is capable of being totally or partially selectively retained in the tumor, provided that when the compound is locally administered intratumorally under controlled and optimized conditions of dose, flow rate, volume, and fluid pressure, then the compound is capable of causing total or partial tumor elimination and optionally minimized secondary toxicity effects on healthy tissues.

[0009] In some embodiment, according to the method disclosed herein, the method is indicated for subjects, wherein the subject is a human patient, a laboratory rodent, a farm animal, a livestockanimal, or a domestic animal. Tn some embodiments, the subject is a human patient. In some embodiments, the subject is a laboratory rodent (e.g., mice). In some embodiments, the subject is a farm animal (e.g., a horse). In some embodiments, the subject is a livestock animal. In some embodiments, the subject is a domestic animal (e.g., a pet, a dog, or a cat).

[0010] In some embodiments, according to the method disclosed the pathological condition or disease in the subject is cancer, wherein the subject has one or more than one tumor.

[0011] In one aspect, the method disclosed is for the treatment of tumors, wherein the tumor elimination is the result of tumor death.

[0012] In other aspects, the method discloses that the compound is an organic molecule with specific chemical and physical properties, wherein the molecule has at least one or more of the following chemical or physical properties:A) is retained selectively within the tumor,B) has poor systemic circulation in the bloodstream,C) has poor systemic diffusion in the body,D) has low solubility in water,E) has a high binding capacity to the tumor’s molecular components,F) has a low binding preference for the plasma components and preferential binding to tissues including tumors,G) has low oral absorption resulting in low oral availability, orH) all the above summarizes in that the molecule has a poor pharmacokinetics profile, not suitable for oral, intravenous or intraperitoneal administration.

[0013] In some embodiments, the present method further discloses a specific compound name that is uniquely retained in the tumor at high concentrations upon intratumoral administration and is capable of causing death of the tumor, wherein the compound is further defined as: 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)- 1 , 1 -dimethyl-2-((E)-2-((E)-3 -((E)-2-( 1 , 1 ,3 -trimethyl- 1,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium.

[0014] In some embodiments, the present method further discloses specific compound names with chemical properties for high retention in the tumor and are capable of causing the death of the tumor or delay the growth of the tumor, where the compound is further defined as a dye: Acridine orange 10-nonyl (NAO), methylene blue, 1,9-dimethyl methylene blue, benzalkonium chloride, crystal violet, rhodamine, rhodamine 800, basic red 5 dye, basic blue 1 dye, nile red dye, rosamine-based dyes, mitotracker red dye, and aminocyanine.

[0015] In some embodiments, the method herein further discloses existing compounds in clinical trials where their development has been hindered or halted due to poor pharmacokinetics profile, where the compound is further defined as one of the existing drugs with poor pharmacokinetics profiles: Tivantinib (ARQ 197), Irinotecan, Sorafenib, Sorafenib Analog XL999, BAY 43-9006 (Preclinical Sorafenib Derivative), Paclitaxel (Taxol), Venetoclax (Venclexta), Vismodegib (Erivedge), Dasatinib (Spry cel), Epothilones A and B (Natural Epothilones), Bryostatin-1, Flavopiridol (Alvocidib), Tanespimycin (17-AAG), XL 184 (Preclinical Cabozantinib Analog), PR-104, LY293111, DMXAA (Vadimezan), Marizomib (NPI-0052), Epothilone B Derivatives, Obatoclax, Bexarotene Analog (RXR Agonist), SNS-032, IPI-504 (Retaspimycin), XL281, and GRN163L (Imetelstat Precursor).

[0016] In some embodiments, the method uses medical devices for the administration of the compounds to optimize the distribution or perfusion within the tumor while minimizing the rupture of the tumor and avoiding leakage of the compound outside the tumor, wherein a medical device is used to administer or deliver the compound intratumorally. In some embodiments, the compound is injected under controlled and optimized conditions of injected dose, flow rate, injected volume, and fluid pressure to prevent tumor rupture, and maximize compound retention in the tumor and minimize leakage of the compound.

[0017] In some embodiments, the method is further described, wherein the flow rate, injected volume, and fluid pressure are controlled by a programmable automated syringe pump.

[0018] In other embodiments, the method is further described, wherein the flow rate, injected volume, and fluid pressure are controlled by a syringe operated by a skilled or trained healthcare practitioner.

[0019] In other embodiments, the method is further described, wherein a catheter with a needle or a thin plastic tube with a needle for intratumoral injection is connected to the syringe.

[0020] In some embodiments, the method is further described, wherein the medical device is a laparoscope, an endoscope, or a stereotactic system, for assisting in inserting intratumorally the needle of the catheter or microcatheter.

[0021] In some embodiments, the method is optionally further described, wherein the medical device is a miniaturized robotic mechanism.

[0022] In some embodiments, the method is further described, wherein the conditions for intratumoral injection are comprising:A) A dose of the compound in the range of 1 pM to 1000 mM of an injected volume of 0.001 mL to 0.5 mL per each cm3(mL / cm3) of the tumor. For example, in one embodiment, the concentration of the compound may comprise, 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 10 pM, 15 pM, 20 pM, 25 pM, 30 pM, 35 pM, 40 pM, 45 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 120 pM, 140 pM, 160 pM, 180 pM, 200 pM, 220 pM, 240 pM, 260 pM, 280 pM, 300 pM, 320 pM, 340 pM, 360 pM, 380 pM, 400 pM, 420 pM, 440 pM, 460 pM, 480 pM, 500 pM, 600 pM, 700 pM, 800 pM, 900 pM, 1000 pM, 1100 pM, 1200 pM, 1300 pM, 1400 pM, 1500 pM, 1600 pM, 1700 pM, 1800 pM, 1900 pM, 2000 pM, 2100 pM, 2200 pM, 2300 pM, 2400 pM, 2500 pM, 3000 pM, 4000 pM, 5000 pM, 6000 pM, 7000 pM, 8000 pM, 9000 pM, 10000 pM, 20000 pM, 30000 pM, 40000 pM, 50000 pM, 60000 pM, 70000 pM, 80000 pM, 90000 pM, 100000 pM, 150000 pM, 200000 pM, 250000 pM, 300000 pM, 350000 pM, 400000 pM, 450000 pM, 500000 pM, 550000 pM, 600000 pM, 650000 pM, 700000 pM, 750000 pM, 800000 pM, 850000 pM, 900000 pM, 950000 pM, or 1000000 pM. Additionally, in another embodiment, the injected volume may comprise, 0.001 mL / cm3, 0.002 mL / cm3, 0.003 mL / cm3, 0.004 mL / cm3, 0.005 mL / cm3, 0.006 mL / cm3, 0.007 mL / cm3, 0.008 mL / cm3, 0.009 mL / cm3, 0.010 mL / cm3, 0.015 mL / cm3, 0.020 mL / cm3, 0.025 mL / cm3, 0.030 mL / cm3, 0.035 mL / cm3, 0.040 mL / cm3, 0.045 mL / cm3, 0.050 mL / cm3, 0.060 mL / cm3, 0.070 mL / cm3, 0.080 mL / cm3, 0.090 mL / cm3, 0.100 mL / cm3, 0.105 mL / cm3, 0.110 mL / cm3, 0.115 mL / cm3, 0.120 mL / cm3, 0.125 mL / cm3, 0.130 mL / cm3, 0.135 mL / cm3, 0.140 mL / cm3, 0.145 mL / cm3, 0.150 mL / cm3, 0.155 mL / cm3, 0.160 mL / cm3, 0.165 mL / cm3, 0.170 mL / cm3, 0.175 mL / cm3, 0.180 mL / cm3, 0.185 mL / cm3, 0.190 mL / cm3, 0.195 mL / cm3, 0.200 mL / cm3, 0.210 mL / cm3, 0.220 mL / cm3, 0.230 mL / cm3, 0.240 mL / cm3, 0.250 mL / cm3, 0.260 mL / cm3, 0.270 mL / cm3, 0.280 mL / cm3, 0.290 mL / cm3, 0.300 mL / cm3, 0.310 mL / cm3, 0.320 mL / cm3, 0.330 mL / cm3, 0.340 mL / cm3, 0.350 mL / cm3, 0.360 mL / cm3, 0.370 mL / cm3, 0.380 mL / cm3, 0.390 mL / cm3, 0.400 mL / cm3, 0.410 mL / cm3, 0.420mL / cm3, 0.430 mL / cm3, 0.440 mL / cm3, 0.450 mL / cm3, 0.460 mL / cm3, 0.470 mL / cm3, 0.480 mL / cm3, 0.490 mL / cm3, 0.491 mL / cm3, 0.492 mL / cm3, 0.493 mL / cm3, 0.494 mL / cm3, 0.495 mL / cm3, 0.496 mL / cm3, 0.497 mL / cm3, 0.498 mL / cm3, 0.499 mL / cm3, or 0.500 mL / cm3. Preferentially high concentration of 7000 pM or higher, and injected volume preferentially from 0.1 to 0.2 mL / cm3of tumor;B) A flow rate between the range of 0.001 mL per min to 2.0 mL per min, preferentially between 0.1 to 0.5 mL per min. For example, in an embodiment, the flow rate may comprise, 0.001 mL per min, 0.002 mL per min, 0.003 mL per min, 0.004 mL per min, 0.005 mL per min, 0.006 mL per min, 0.007 mL per min, 0.008 mL per min, 0.009 mL per min, 0.010 mL per min, 0.015 mL per min, 0.020 mL per min, 0.025 mL per min, 0.030 mL per min, 0.035 mL per min, 0.040 mL per min, 0.045 mL per min, 0.050 mL per min, 0.060 mL per min, 0.070 mL per min, 0.080 mL per min, 0.090 mL per min, 0.100 mL per min, 0.150 mL per min, 0.200 mL per min, 0.250 mL per min, 0.300 mL per min, 0.350 mL per min, 0.400 mL per min, 0.450 mL per min, 0.500 mL per min, 0.550 mL per min, 0.600 mL per min, 0.650 mL per min, 0.700 mL per min, 0.750 mL per min, 0.800 mL per min, 0.850 mL per min, 0.900 mL per min, 0.950 mL per min, 1.000 mL per min, 1.050 mL per min, 1.100 mL per min, 1.150 mL per min, 1.200 mL per min, 1.250 mL per min, 1.300 mL per min, 1.350 mL per min, 1.400 mL per min, 1.450 mL per min, 1.500 mL per min, 1.550 mL per min, 1.600 mL per min, 1.650 mL per min, 1.700 mL per min, 1.750 mL per min, 1.800 mL per min, 1.850 mL per min, 1.900 mL per min, 1.950 mL per min, or 2.000 mL per min;C) An injected volume and flow rate balance that the resulting intratumoral fluid pressure does not exceed the rupture pressure (approximately 150-200 mmHg). For example, in an embodiment, the rupture pressure may comprise 150 mmHg, 155 mmHg, 160 mmHg, 165 mmHg, 170 mmHg, 175 mmHg, 180 mmHg, 185 mmHg, 190 mmHg, 195 mmHg, or 200 mmHg.

[0023] In some embodiments, the method is further described with examples, wherein the technical specifications for intratumoral drug delivery using laparoscopy in many tumor types, including but not limited to: pancreatic, liver, and ovarian.

[0024] In some embodiments, the method is further described with examples, wherein the technical specifications for intratumoral drug delivery using endoscopy in many tumor types, including but not limited to: colorectal, head and neck, bladder, and cervical.

[0025] In some embodiments, the method is further described with examples, wherein the technical specifications for intratumoral drug delivery using small surgery incision and / or syringes operated by a trained health provider in many tumor types, including but not limited to: thyroid, oral cancers, and melanoma. Here the claims are for the technical specifications of the composition and the injection conditions for maximizing intratumoral retention, avoiding tumor rupture, and minimizing leakage of the compound.

[0026] In some embodiments, the technical specifications for using stereotactically placed microcatheters to deliver a high-concentration drug solution intratumorally in brain tumors.

[0027] In some embodiments, the method is optionally further described, wherein optionally the compound is exposed to light or electromagnetic radiation of wavelength between 400 nm to 2300 nm. More specifically, the light therapeutic windows can be: 1) first window (NIR-I), approximately from 650 nm to 950 nm, 2) second window (NIR-II) approximately from 1000 nm to 1350 nm, 3) third window (NIR-III) approximately from 1500 nm to 1800 nm, and 4) the emerging NIR-IV Window (2100-2300 nm). In some aspects, the method is optionally integrated with a light source, wherein the light source is an optical fiber or LED array embedded in the catheter or microcatheter or integrated into the medical device for photoactivation or photoexcitation. The light source can be a continuous wave (CW), pulsed laser, a pulsed lightemitting diode (LED), or a continuous wave LED. In other optional aspects, wherein optionally exposing the compound to light results in enhanced therapeutic efficacy through phototherapy activation. In another aspect, wherein phototherapy activation can be photodynamic, photothermal, photomechanical, photoimmunotherapy, photoactivated chemotherapy, or a combination thereof. Low optical power (irradiance) and high optical powers can be used. The irradiance can be as low as approximately 10 pW / cm2and as high as approximately 50 W / cm2. For example, in an embodiment, the irradiance may comprise 10 pW / cm2, 20 pW / cm2, 30 pW / cm2, 40 pW / cm2, 50 pW / cm2, 60 pW / cm2, 70 pW / cm2, 80 pW / cm2, 90 pW / cm2, 100 pW / cm2, 120 pW / cm2, 140 pW / cm2, 160 pW / cm2, 180 pW / cm2, 200 pW / cm2, 250 pW / cm2, 300 pW / cm2, 350 pW / cm2, 400 pW / cm2, 450 pW / cm2, 500 pW / cm2, 600 pW / cm2, 700 pW / cm2, 800 pW / cm2, 900 pW / cm2, 1000 pW / cm2, 1100 pW / cm2, 1200 pW / cm2, 1300 pW / cm2, 1400 pW / cm2, 1500 pW / cm2, 1600 pW / cm2, 1700 pW / cm2, 1800 pW / cm2, 1900 pW / cm2, 2 mW / cm2, 3 mW / cm2, 4 mW / cm2, 5 mW / cm2, 10 mW / cm2, 20 mW / cm2, 30 mW / cm2, 40 mW / cm2, 45 mW / cm2, 46 mW / cm2, 47 mW / cm2, 48 mW / cm2, 49 mW / cm2, 50 mW / cm2, 51 mW / cm2, 52 mW / cm2, 53 mW / cm2, 54mW / cm2, 55 mW / cm260 mW / cm2, 65 mW / cm2, 70 mW / cm2, 75 mW / cm2, 80 mW / cm2, 85 mW / cm2, 90 mW / cm2, 95 mW / cm2, 100 mW / cm2, 105 mW / cm2, 110 mW / cm2, 115 mW / cm2, 120 mW / cm2, 125 mW / cm2, 130 mW / cm2, 135 mW / cm2, 140 mW / cm2, 145 mW / cm2, 150 mW / cm2, 155 mW / cm2, 160 mW / cm2, 165 mW / cm2, 170 mW / cm2, 175 mW / cm2, 180 mW / cm2, 185 mW / cm2, 190 mW / cm2, 195 mW / cm2, 200 mW / cm2, 205 mW / cm2, 210 mW / cm2, 215 mW / cm2, 220 mW / cm2, 225 mW / cm2, 230 mW / cm2, 235 mW / cm2, 240 mW / cm2, 245 mW / cm2, 250 mW / cm2, 255 mW / cm2, 260 mW / cm2, 265 mW / cm2, 270 mW / cm2, 275 mW / cm2, 280 mW / cm2, 285 mW / cm2, 290 mW / cm2, 295 mW / cm2, 300 mW / cm2, 305 mW / cm2, 310 mW / cm2, 315 mW / cm2, 320 mW / cm2, 325 mW / cm2, 330 mW / cm2, 335 mW / cm2, 340 mW / cm2, 345 mW / cm2, 350 mW / cm2, 355 mW / cm2, 360 mW / cm2, 365 mW / cm2, 370 mW / cm2, 375 mW / cm2, 380 mW / cm2, 385 mW / cm2, 390 mW / cm2, 395 mW / cm2, 400 mW / cm2, 405 mW / cm2, 410 mW / cm2, 415 mW / cm2, 420 mW / cm2, 425 mW / cm2, 430 mW / cm2, 435 mW / cm2, 440 mW / cm2, 445 mW / cm2, 450 mW / cm2, 455 mW / cm2, 460 mW / cm2, 465 mW / cm2, 470 mW / cm2, 475 mW / cm2, 480 mW / cm2, 485 mW / cm2, 490 mW / cm2, 495 mW / cm2, 496 mW / cm2, 497 mW / cm2, 498 mW / cm2, 499 mW / cm2, 500 mW / cm2, 501 mW / cm2, 502 mW / cm2, 503 mW / cm2, 504 mW / cm2, 505 mW / cm2, 510 mW / cm2, 515 mW / cm2, 520 mW / cm2, 525 mW / cm2, 530 mW / cm2, 535 mW / cm2, 540 mW / cm2, 545 mW / cm2, 550 mW / cm2, 600 mW / cm2, 700 mW / cm2, 800 mW / cm2, 900 mW / cm2, 1 W / cm2, 2 W / cm2, 3 W / cm2, 4 W / cm2, 5 W / cm2, 10 W / cm2, 15 W / cm2, 20 W / cm2, 25 W / cm2, 30 W / cm2, 35 W / cm2, 40 W / cm2, 45 W / cm2, or 50 W / cm2. For low-level light therapy (LLLT), the irradiance is preferred below 100 mW / cm2. For high-level light therapy (HLLT), the irradiance is preferred above 100 mW / cm2. The time of light exposure can be from about 1 picosecond up to about 600 minutes. For example, in an embodiment, the time of light exposure may comprise 1 ps, 2 ps, 3 ps, 4 ps, 5 ps, 10 ps, 15 ps, 20 ps, 25 ps, 30 ps, 35 ps, 40 ps, 45 ps, 50 ps, 60 ps, 70 ps, 80 ps, 90 ps, 100 ps, 150 ps, 200 ps, 250 ps, 300 ps, 350 ps, 400 ps, 450 ps, 500 ps, 600 ps, 700 ps, 800 ps, 900 ps, 1000 ps, 1100 ps, 1200 ps, 1300 ps, 1400 ps, 1500 ps, 1600 ps, 1700 ps, 1800 ps, 1900 ps, 2 ns, 3 ns, 4 ns, 5 ns, 6 ns, 7 ns, 8 ns, 9 ns, 10 ns, 15 ns, 20 ns, 25 ns, 30 ns, 35 ns, 40 ns, 45 ns, 50 ns, 60 ns, 70 ns, 80 ns, 90 ns, 100 ns, 150 ns, 200 ns, 250 ns, 300 ns, 350 ns, 400 ns, 450 ns, 500 ns, 600 ns, 700 ns, 800 ns, 900 ns, 1000 ns, 1100 ns, 1200 ns, 1300 ns, 1400 ns, 1500 ns, 1600 ns, 1700 ns, 1800 ns, 1900 ns, 2 ps, 3 ps, 4 ps, 5 ps, 6 ps, 7 ps, 8 ps, 9 ps, 10 ps, 15 ps, 20 ps, 25 ps, 30 ps, 35 ps, 40 ps, 45 ps, 50 ps, 60 ps, 70 ps, 80 ps, 90 ps, 100 ps, 150 ps, 200 ps, 250 ps, 300 ps, 350 ps, 400 ps, 450 ps, 500 ps, 600 ps, 700 ps, 800 ps, 900 ps,1000 is, 1100 pis, 1200 pis, 1300 ps, 1400 ps, 1500 ps, 1600 ps, 1700 ps, 1800 ps, 1900 ps, 2 ms, 3 ms, 4 ms, 5 ms, 6 ms, 7 ms, 8 ms, 9 ms, 10 ms, 15 ms, 20 ms, 25 ms, 30 ms, 35 ms, 40 ms, 45 ms, 50 ms, 60 ms, 70 ms, 80 ms, 90 ms, 100 ms, 150 ms, 200 ms, 250 ms, 300 ms, 350 ms, 400 ms, 450 ms, 500 ms, 600 ms, 700 ms, 800 ms, 900 ms, 1000 ms, 1100 ms, 1200 ms, 1300 ms, 1400 ms, 1500 ms, 1600 ms, 1700 ms, 1800 ms, 1900 ms, 2 s, 3 s, 4 s, 5 s, 6 s, 7 s, 8 s, 9 s, 10 s, 15 s, 20 s, 25 s, 30 s, 35 s, 40 s, 45 s, 50 s, 60 s, 70 s, 80 s, 90 s, 100 s, 110 s, 120 s, 130 s, 140 s, 150 s, 160 s, 170 s, 180 s, 190 s, 200 s, 210 s, 220 s, 230 s, 240 s, 250 s, 260 s, 270 s, 280 s, 290 s, 300 s, 310 s, 320 s, 330 s, 340 s, 350 s, 360 s, 370 s, 380 s, 390 s, 400 s, 410 s, 420 s, 430 s, 440 s, 450 s, 460 s, 470 s, 480 s, 490 s, 500 s, 510 s, 520 s, 530 s, 540 s, 550 s, 560 s, 570 s, 580 s, 590 s, 600 s, 610 s, 620 s, 630 s, 640 s, 650 s, 660 s, 670 s, 680 s, 690 s, 700 s, 710 s, 720 s, 730 s, 740 s, 750 s, 760 s, 770 s, 780 s, 790 s, 800 s, 810 s, 820 s, 830 s, 840 s, 850 s, 860 s, 870 s, 880 s, 890 s, 900 s, 910 s, 920 s, 930 s, 940 s, 950 s, 960 s, 970 s, 980 s, 990 s, 1000 s, 1010 s, 1020 s, 1030 s, 1040 s, 1050 s, 1060 s, 1070 s, 1080 s, 1090 s, 1100 s, 1110 s, 1120 s, 1130 s, 1140 s, 1150 s, 1160 s, 1170 s, 1180 s, 1190 s, 1200 s, 1210 s, 1220 s, 1230 s, 1240 s, 1250 s, 1260 s, 1270 s, 1280 s, 1290 s, 1300 s, 1310 s, 1320 s, 1330 s, 1340 s, 1350 s, 1360 s, 1370 s, 1380 s, 1390 s, 1400 s, 1410 s, 1420 s, 1430 s, 1440 s, 1450 s, 1460 s, 1470 s, 1480 s, 1490 s, 1500 s, 1510 s, 1520 s, 1530 s, 1540 s, 1550 s, 1560 s, 1570 s, 1580 s, 1590 s, 1600 s, 1610 s, 1620 s, 1630 s, 1640 s, 1650 s, 1660 s, 1670 s, 1680 s, 1690 s, 1700 s, 1710 s, 1720 s, 1730 s, 1740 s, 1750 s, 1760 s, 1770 s, 1780 s, 1790 s, 1800 s, 1810 s, 1820 s, 1830 s, 1840 s, 1850 s, 1860 s, 1870 s, 1880 s, 1890 s, 1900 s, 2000 s, 2100 s, 2200 s, 2300 s, 2400 s, 2500 s, 2600 s, 2700 s, 2800 s, 2900 s, 3000 s, 3100 s, 3200 s, 3300 s, 3400 s, 3500 s, 3600 s, 3700 s, 3800 s, 3900 s, 4000 s, 4100 s, 4200 s, 4300 s, 4400 s, 4500 s, 4600 s, 4700 s, 4800 s, 4900 s, 5000 s, 5500 s, 6000 s, 6500 s, 7000 s, 7500 s, 8000 s, 8500 s, 9000 s, 9500 s, 10000 s, 11000 s, 12000 s, 13000 s, 14000 s, 15000 s, 16000 s, 17000 s, 18000 s, 19000 s, 20000 s, 21000 s, 22000 s, 23000 s, 24000 s, 25000 s, 26000 s, 27000 s, 28000 s, 29000 s, 30000 s, 31000 s, 32000 s, 33000 s, 34000 s, 35000 s, or 36000 s. For LLLT, the exposure time is preferentially minutes to hours (preferentially from 1 min to 600 minutes depending on the irradiance). For HLLT, the light exposure is preferentially from 1 picosecond to 30 min. In the HLLT, high-power pulsed lasers, LED, and CW lasers can be used. The purpose of photoactivation is to provide or activate the molecules for an additional killing mechanism since many of these molecules are known to be light absorbers for phototherapy. Especially the group of molecules defined as dyes: Acridine orange 10-nonyl (NAO), methylene blue, 1,9-dimethyl methylene blue,benzalkonium chloride, crystal violet, rhodamine, rhodamine 800, basic red 5 dye, basic blue 1 dye, nile red dye, rosamine-based dyes, mitotracker red dye, and cyanines. Many of these dyes can not advance toward clinical trials in humans and to the market because of issues with poor pharmacokinetics profdes. The method disclosed herein for intratumoral administration now can allow to use of this type of compound to solve the issues of poor solubility, high retention in the liver and lungs, and poor pharmacokinetics profdes. Otherwise, those compounds cannot advance clinical trials to treat tumors in a patient. This disclosure also makes possible the use of these compounds for phototherapies in the clinic, including photodynamic, photothermal, photomechanical, photoimmunotherapy, photoactivated chemotherapy, or a combination thereof. Otherwise, the research community needs to develop alternative compounds with better pharmacokinetics profdes. However, by improving the pharmacokinetics the pharmacology can be compromised, namely adding a chemical group to the anticancer molecule for tumor targeting or better systemic biodistribution can hinder the anticancer potency..

[0028] The mechanism of action of the compound for causing tumor death could include, but is not limited to, apoptosis, necrosis, autophagy, necroptosis, pyroptosis, ferroptosis, and immunogenic cell death. Additionally, the activation of immune system signals could lead to the abscopal effect (elimination of tumors at distant sites from the original treatment by immune system activation).BRIEF DESCRIPTION OF DRAWINGS

[0029] FIG. 1. Shows a schematic representation of the method, a therapeutic molecule, and devices. A) Anticancer molecule. Small molecules as anticancer drugs in this method can have one or more of the following characteristics: high tumor retention, anticancer activity, poor systemic circulation / diffusion, low solubility, and high tumor binding. The molecule in the drawing is acridine orange 10-nonyl (NAO). B) The device and important parameters for the optimum intratumoral delivery. The purpose of the intratumoral -injecting device is to optimize perfusion within the tumor and minimize leakage: injection rate, volume, and pressure are controlled. C) Experimental subjects for this application: human, small laboratory rodents, and large animals (e.g., horses, dogs).

[0030] FIG. 2. Provides the chemical structure and evidence for the high tumor retention of aminocyanine molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l , 1 ,3-trimethyl-l ,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l -en-1 -yl)vinyl)-lH-benzo[e]indol-3-ium. A) Chemical structure of the molecule. 10) Indicates the benzene ring in the benzoindole, which contributes to retention in the tumor. 20) Indicates the chemical functional group that contributes to binding and retention in the tumor. B) Mice with pancreatic cancer tumors implanted subcutaneously on the right -leg. Tumor injected with aminocyanine in-tratumorally. The green-dark color corresponds to the aminocyanine color. The aminocyanine can be observed by human sight. This is one of the advantages of this invention. There is no need to use sophisticated imaging instrumentation to visualize the retention of the compound. The images correspond to 1 day after treatment. See that the aminocyanine is highly retained in the tumor after day (1 d). Injection volume = 0.2 mb per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size ~100 mm3~ 0.1 g. The aminocyanine delays the tumor growth relative to the control. Representative images. C) Tumor injected with PBS solution (control). D) Quantification of the color intensity in the tumor versus in the non-tumor area (background). The aminocyanine dye is dark green in color. For this reason, the color intensity (darker color) is lower when the dye is present in the tumor area, in contrast to the non-tumor area (background). E) Averaged color intensities. F) Lipinski’s rule of five property calculator shows the molecule has two violations of the criteria.

[0031] FIG. 3 Provides evidence of the therapeutic efficacy of intratumorally injected molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trime-thyl- 1 ,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex- 1 -en- 1 -y 1 )viny 1 )- 1H-benzo[e]indol-3-ium against pancreatic cancer tumors implanted in nude mice. The molecule is injected at 7.5 mM concentration in a solution containing a mixture of 5% DMSO in PBS buffer. The control is 5% DMSO in PBS. The total injected volume was 20 pL. Injection volume « 0.2 mb per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size ~100 mm3« 0.1 g. The molecule was injected at day 1, day 3 and day 8.

[0032] FIG.4. Shows the comparison of the molecule containing benzoindole (commonly known as Cy7.5) in contrast to the molecule with indole (commonly known as Cy7). A) Cy7.5 molecule: 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trime-thyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. B) Cy7 molecule. Lipinski’s rule of five property calculation is shown for both molecules. The comparison of figure panels A and B shows that the benzoindole in Cy7.5 hasan important influence on the Lipinski’s rule of five predictor, showing that Cy7.5 is less soluble in water (higher logP value) and therefore contributes to a better retention in the tumor.

[0033] FIG. 5. Shows evidence of intratumoral retention of aminocyanine molecule 2 days after treatment. The molecule is 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. A) Tumor injected with aminocyanine molecule intratumorally. B) Tumor injected with PBS solution (control). The green -dark color corresponds to the aminocyanine color. The aminocyanine can be observed by human sight (This is one of the advantages of this invention). No need to use sophisticated imaging instrumentation. The images correspond to 2 days after the treatment. See that the molecule is highly retained in the tumor after 2 days. The molecule delays the tumor growth. Injection volume « 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. The molecule is injected at 7.5 mM concentration in a solution containing a mixture of 5% DMSO in PBS buffer. The control is 5% DMSO in PBS.

[0034] FIG. 6 Provides evidence that the aminocyanine molecule is retained in the tumor even 7 days after the injection, and the growth of the tumor is delayed. It shows mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. The injected aminocyanine molecule is 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trime-thyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. A) Tumor injected with the aminocyanine intratumorally. B) Tumor injected with PBS solution (control). The green-dark color corresponds to the aminocyanine color. The aminocyanine can be observed by human sight (This is one of the advantages of this invention). No need to use sophisticated imaging instrumentation. The images correspond to 7 days after the first treatment. See that the aminocyanine is highly retained in the tumor after several days (7 d). The aminocyanine delays the tumor growth. Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min.

[0035] FIG.7. Provides evidence that the aminocyanine is highly retained in the tumor at 1 h after injection through fluorescence detection. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. A) Tumor injected with aminocyanine intratumorally. B) Tumor injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 1 h after treatment. Injection volume ~ 0.2 mL pergram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size —100 mm3- 0.1 g. C) Quantification of the fluorescence intensity on images in panels A and B. The fluorescence intensity values are normalized with respect to the baseline intensity in the skin at the non-tumor area in the control mouse. The fluorescence intensity of the tumor area is about 50-fold relative to the intensity of the skin at the non-tumor area, which is indicative of important retention of aminocyanine in the tumor.

[0036] FIG. 8 Provides evidence that the aminocyanine is highly retained in the tumor at 24 h after injection through fluorescence detection. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. A) Tumor injected with aminocyanine intratumorally. B) Tumor injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 24 h after treatment. Injection volume = 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size -100 mm3- 0.1 g.C) Quantification of the fluorescence intensity on images in panels A and B. The fluorescence intensity values are normalized with respect to the baseline intensity in the skin at the non-tumor area in the control mouse. The fluorescence intensity of the tumor area is about 30-fold relative to the intensity of the skin at the non-tumor area, which is indicative of important retention of aminocyanine in the tumor.

[0037] FIG. 9 Provides evidence that the aminocyanine is highly retained in the tumor at 48 h after injection through fluorescence detection. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. A) Tumor injected with aminocyanine intratumorally. B) Tumor injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 48 h after treatment. See that the aminocyanine is highly retained in the tumor after 1 h. Injection volume - 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size -100 mm3— 0.1 g. C) Quantification of the fluorescence intensity on images in panels A and B. The fluorescence intensity values are normalized with respect to the baseline intensity in the skin at the non-tumor area in the control mouse. The fluorescence intensity of the tumor area is about 20-fold relative to the intensity of the skin at the non-tumor area, which is indicative of important retention of aminocyanine in the tumor.

[0038] FIG. 10 Provides evidence that the molecule can leak outside the tumor when it is not appropriately injected under unoptimized conditions of dose per mass of tumor and flow rate. It illustrates the importance of the parameters and use of a medical device (e.g., syringe pump) for better control to maximize retention and avoid tumor rupture. A) Mice with pancreatic cancertumors were implanted subcutaneously on the right leg. The tumor was injected with aminocyanine intratumorally. The color in the tumor area corresponds to the fluorescence emission from aminocyanine. Injection volume ~ 0.4 mL per gram of tumor. Injection rate: 8 pL / s = 0.5 mL / min. B) Quantification of the fluorescence intensity on images in panel A. The fluorescence intensity values are normalized with respect to the baseline intensity in the skin at the non-tumor area before injection (mouse labeled as initial). The fluorescence intensity of the tumor area is only about 2-fold relative to the intensity of the skin at the non-tumor area, which is indicative of important leakage of aminocyanine outside the tumor.DETAILED DESCRIPTION OF THE INVENTION

[0039] This present disclosure describes small molecules and a new method to obtain high intratumoral therapeutic concentration and retention for selective tumor death, while sparing healthy tissues and minimizing toxicity side effects, as an alternative process and composition of the existing highly toxic cancer treatments in the pharmaceutical and healthcare industry.

[0040] In the disclosure herein high intratumoral retention refers to nearly 90%-100% of the injected dose being retained in the tumor. In contrast, to the systemic administration routes (e.g., intravenous, oral, intraperitoneal, intramuscular) where approximately 1-5% of the administered dose reaches the tumor in the best cases and most is retained on the liver and other organs, and / or rapidly excreted or metabolized. In other cases in the invention herein, high tumor retention can be considered more than 10% of the injected dose, larger than 10%, ideally close to 100%. In general high tumor retention can be also a percentage value deduced between approximately about 10% to 100%. For example, in an embodiment, the compound could have a retention comprising 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90.0%, 90.1%, 90.2%, 90.3%, 90.4%, 90.5%, 90.6%, 90.7%, 90.8%, 90.9%, 91.0%, 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, 91.6%, 91.7%, 91.8%, 91.9%, 92.0%, 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, 92.6%, 92.7%, 92.8%, 92.9%, 93.0%, 93.1%, 93.2%, 93.3%, 93.4%, 93.5%, 93.6%, 93.7%, 93.8%, 93.9%, 94.0%, 94.1%, 94.2%, 94.3%, 94.4%, 94.5%, 94.6%, 94.7%, 94.8%, 94.9%, 95.0%,95.1%, 95.2%, 95.3%, 95.4%, 95.5%, 95.6%, 95.7%, 95.8%, 95.9%, 96.0%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97.0%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98.0%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100.0%.

[0041] In this disclosure, small molecules can also be referred to as compounds, chemicals, molecular structures, chemotherapeutic agents, drugs, or similar common names. The small molecules in the disclosure herein refer to molecules that have the intrinsic property to be highly retained in the tumor at high concentrations and with intrinsic high therapeutic potency to eliminate tumors.

[0042] The small molecules in this disclosure have antitumor therapeutic activity (anticancer activity) and could have at least one of the following properties but not limited to: 1) high tumor retention, 2) poor systemic circulation in the body, 3) poor systemic diffusion in the body, 4) low solubility in water, 5) high binding to tumor’s molecular components which can be selective but not necessarily in some cases, 6) low binding preference to plasma components in the blood and high preferential binding to solid tissues including tumors, 7) low oral absorption resulting in low oral availability, 8) the molecule could be not suitable for oral, intravenous, intraperitoneal administration due to the poor absorption and distribution issues (poor pharmacokinetics profde). In summary, these molecules have a poor pharmacokinetics profile. When these molecules are locally injected intratumorally, the absorption and distribution issues can be avoided, and in contrast the tumor binding and retention are enhanced, resulting in a potent and selective antitumor treatment.

[0043] Typically, better pharmacokinetics profiles (e.g., higher absorption or permeation and distribution or diffusion) are desired in drug development. The compositions disclosed herein are counterintuitive to what the pharmaceutical industry and academic researchers seek in a drug to reach the market. Molecules with poor pharmacokinetics profiles are used herein which were or could be discontinued from the drug development process. This apparent misconceived disadvantage, the poor pharmacokinetics profile, herein is used as an advantage for high tumor retention and high potent tumor eradication.

[0044] Acridine orange 10-nonyl (NAO), methylene blue, 1,9-dimethyl methylene blue, benzalkonium chloride, crystal violet, rhodamine, rhodamine 800, basic red 5 dye, basic blue 1dye, nile red dye, rosamine-based dyes and mitotracker red dye can be used as anti cancer or antitumor drugs with high intratumoral retention.

[0045] Described herein is a method to obtain a nearly selective and specific antitumor therapeutic activity using a small molecule and a device for local intratumoral injection (FIG. 1). The main component is the small molecule that is retained in the tumor and remains highly localized in the tumor due to its chemical and physical properties even after several days after the injection. The intratumoral injection device is important to maximize the small molecule perfusion in the tumor and minimizing leakage. This is possible by controlling: 1) the injection rate (or injection speed: injected volume per time), 2) the injected volume or more specifically the volume injected per mass of tumor, and 3) the intratumoral pressure. All of these are important to avoid the rupture of the tumor and leakage of the drug.

[0046] The main purpose of the device is to control the injection parameters (including: injection rate, injection volume, and pressure) for maximizing drug perfusion and retention while preventing the rupture of the tumor and minimizing leakage. And a second purpose is to reach deep-seated tumors. The main component is a syringe and a syringe pump that controls the injection parameters. A catheter (a thin flexible plastic tube with a needle to end for intratumoral insertion) can be utilized to inject intratum orally the small molecule in solution for superficial tumors such as melanoma, oral cancers, and breast cancer tumors, among others. (FIG. IB). Optionally, a laparoscope (minimally invasive laparoscopic surgery) can be utilized to bring the catheter and inject the molecule into deep-seated tumors such as pancreatic, liver tumors, ovarian tumors, and kidney tumors, among others. Optionally, a noninvasive endoscope can be utilized to bring the catheter and inject the molecule into tumors localized on open cavities in the body, including gastrointestinal cancers (e.g. colorectal tumors, stomach tumors), oral cancers, cervical cancers, and bladder cancers, among others. Optionally, a healthcare practitioner, skilled in the field to control the injection parameters by hand, can directly inject the therapeutic molecule intratumorally using a syringe (FIG. IB).

[0047] This method is indicated to be used in human subjects, laboratory animals, domesticated animals (pets), farm animals, and livestock (Fig. 1C). More specifically on subjects having cancer or tumors.

[0048] The therapeutic molecule can be solubilized in water or phosphate buffer saline (PBS) solution or other buffer solutions, or saline solution. For molecules with low solubility in water,an organic solvent can be utilized for initial solubilization and prepared final mixture with water. For example, the therapeutic, small molecule can be solubilized in a mixture of organic solvent and phosphate buffer saline solution (PBS) containing an organic solvent in a range between 0.1% to 100%. For example, in an embodiment, the percentage of organic solvent may comprise 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. The organic solvent can be, and is not limited to: DMSO, ethanol, propanol, isopropanol, methyl ether, acetone, polyethylene glycol, propylene glycol, com oil, cottonseed oil, peanut oil, sesame oil, castor oil, and / or benzyl alcohol.

[0049] With the method disclosed herein, the side effects and toxicity effects can be reduced to nearly zero adverse effects due to the highly localized treatment within the tumor area. This offers an advantage over the highly toxic systemic chemotherapy treatments available in the healthcare industry. And offers an option for the patients that no longer qualify or no longer respond to any of the current available treatments.Technical description

[0050] The method disclosed herein involves the directed and controlled delivery of a drug specifically to the site of pathology, intratumorally in this case. Some highly potent anti-cancer drugs have been discontinued due to low solubility and poor pharmacokinetic profiles, which lead to toxicity issues when administered systemically. Additionally, most available chemotherapy drugs come with various toxicity side effects. The purpose of this disclosure is to address these toxicity issues, as well as challenges related to biodistribution, pharmacokinetics, and crossing biological barriers, such as the blood-brain barrier. There are numerous highly potent drugs and promising candidates for cancer treatment that fail the rules of drug design because their chemical properties lead to poor biodistribution and pharmacokinetic profiles. This invention outlines a method to utilize these drugs effectively to transform a weakness (poor pharmacokinetics) into a strength to overcome these challenges and treat cancer successfully. This approach is non-obvious and counterintuitive because the molecules disclosed herein do not follow the characteristics that are typically desired (good pharmacokinetics profile) in the pharmaceutical industry for chemotherapeutic drugs against cancer.

[0051] The method disclosed herein is controlled and optimized because is done with a device for injection. A syringe pump is used, which injects the drug at a very slow injection rate, at a specificinjection rate of the volume (a molecule in solution or formulation), and a needle to be inserted in the pathological site (a tumor). The medical device can include a thin plastic tube (e.g., a catheter) to transport the volume (a solution or formulation) from the syringe to the needle and release the volume inside the tumor. The molecule solution perfuses or permeates or diffuses radially within the tumor accomplished through the optimum injection rate. This can be accomplished through the use of minimally invasive flexible or rigid tubes (e.g., laparoscope) that are inserted in the body to reach and bring the catheter to the pancreas, brain, esophagus, stomach, intestine, colon, rectum, liver, lung, bladder, vagina, oral cavity. The flexible tube can be a gastrointestinal probe (e.g., endoscope) that is inserted through the mouth, down the esophagus, into the stomach.

[0052] The examples of drugs in this invention are special chemical compounds because of their unique chemical properties. The molecules are highly retained in tumors or localized in the pathological site in the body. The molecule is not recommended for systemic oral, intravenous, or peritoneal administration because of its low circulation and poor pharmacokinetics profile resulting in low accumulation in the tumor. But it's excellent to be injected directly into the tumor and retained in the tumor leading to effective elimination of the tumor. In this invention, what was considered a disadvantage (poor pharmacokinetics profile) is now used as one advantage for intratumoral retention and elimination of the tumor through tumor death.

[0053] The molecule has to be cytotoxic to cancer and highly retained in the tumors. Here we disclose a case of this type molecule, and specific results. To justify this composition subject matter, a particular type of cyanine molecule has the chemical and physical properties for this purpose: 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2- ( 1 , 1 ,3 -trimethyl- 1 ,3 -dihy dro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex- 1 -en- 1 -yl)vinyl)-lH-benzo[e]indol-3-ium (FIG. 2). Simply, this particular molecule within this invention can be called as aminocyanine. However, many cyanine molecules can be collectively called aminocyanines.

[0054] Cyanine dyes have been reported to be cytotoxic to cancer cells since March 2022 (Wangngae et al., 2022) without the need for light activation. However, what is non-obvious and new, or not explored or considered, is that the molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium has poor solubility, poor biodistribution (poor pharmacokinetics profile) in vivo when injected intravenously or any othersystemic routes of administration. This aminocyanine molecule is estimated that less than 1% of the intravenous dose reaches the tumor due to its poor pharmacokinetics (e.g., low circulation in the bloodstream, high retention in the liver, and lungs). Here, what is new, is the use of a disadvantage, the poor pharmacokinetics, (or what most would identify as a weakness) as an advantage to enhance retention of that molecule within the tumor by intratumoral injection. Also, the structural features of 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium (FIG. 2) are significantly different and unique which allows its efficient retention and binding to the tumor. In addition, herein it is disclosed a list of molecules with similar properties in which their drug development toward the market was hindered due to poor pharmacokinetics issues. This is a new and novel way to use these properties of molecules. The chemical properties of particular chemical structures are exploited in a better way. Here we show that this structure is excellent for high retention on the tumors.

[0055] Herein we disclose that the high tumor retention aminocyanine molecule has two violations Lipinski’s criteria, a molecule with a poor pharmacokinetics profile. The structure of the molecule 3 -(6-((6-ammoniohexyl)amino)-6-oxohexyl)- 1 , 1 -dimethyl-2-((E)-2-((E)-3 -((E)-2-( 1,1,3-trimethyl -1,3 -dihy dro-2H-benzo [e]indol -2-y li dene)ethylidene)cy clohex- 1 -en- 1 -y 1 ) vi ny 1 ) - 1 H-benzo[e]indol-3-ium have two violations on the Lipinski’s criteria: 1) the octanol-water-partition coefficient (logP value) higher than 5 and 2) the molecular weight larger than 500 (FIG. 2C). The violation of more than one criterion is a predictor for a poor pharmacokinetics profile. This type of molecule is typically discontinued in the drug development process due to the poor pharmacokinetics profile. In contrast, here we disclose that this criterion can be used as a predictor for high tumoral retention but when the molecule is injected intratumorally.

[0056] Most researchers will synthesize large libraries to enhance solubility, increase pharmacokinetics profile, and decrease toxicity to normal cells. Also, most researchers will try to increase the bioavailability of the cyanines by doing formulations for example with Bovine Serum Albumin (BSA) or other drug delivery strategies. Also, most researchers use strategies to add sulfonic groups to make the molecule more bioavailable and increase the circulation time in the bloodstream. The problem of those strategies is that the potency of the drugs could be significantly reduced hindering its pharmacological effects against cancer. Those strategies have opposing effects to the invention discussed herein.

[0057] Other strategies consider the use of a drug-delivery molecule such as BSA, liposomes, or drug carrier (a larger molecule that can help to transport the cyanine). However, this strategy might be unfruitful because those carriers can compete for the binding of the drug hindering its pharmacological effects and ultimately hindering its therapeutic effects. More negatively, this can happen when the cyanine contains a chlorine atom or substituents in the same position as the reported cytotoxic structure by (Wangngae et al., 2022). This type of cyanine structure containing chlorine atom substituent is well known to react covalently with serum proteins such as BSA or Human Serum Albumin (HSA) which are present in the bloodstream (Usama et al., 2018). In this case, what is improved is the circulation in the bloodstream and retention in the tumor of a covalent complex between cyanine and BSA. Although the cytotoxicity of cyanines without light activation against cancer is not mentioned in this study, it can be easily deduced that this strategy will be unfruitful for cancer therapy since the covalently bound cyanine to BSA will no longer retain its cytotoxic potential against cancer. This case also illustrates how the molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)- 1 , 1 -dimethyl-2-((E)-2-((E)-3 -((E)-2-( 1 , 1 ,3 -trimethyl- 1,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium is different and unique for the disclosure herein which does not contain chlorine atom (FIG.2). This disclosed molecule can retain its intratumoral retention and therapeutic potency against tumors since does not react covalently with serum components such as BSA (FIG. 2B and FIG. 3).

[0058] The molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-( 1,1,3 -trimethyl- 1 ,3 -dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex- 1 -en- 1 -yl)vinyl)-lH-benzo[e]indol-3-ium is different and unique compare to other cyanines. Especially, the benzoindole in this unique cyanine structure makes it more effective for its retention in the tumor when injected intratumorally in contrast with the indole (FIG. 4). The aminocyanine molecule with benzoindole has two violations of Lipinski’s criteria, a molecule with poor pharmacokinetics. The analog molecule with indole has only one violation of Lipinski’s criteria.

[0059] Another aspect is that most researchers will try to add a targeting peptide. It is common for researchers to consider adding one type of chemical motif for targeting such as peptides or aptamers against specific cancer receptors. In nearly all grant applications, specific cancer targeting is requested to be considered in the research strategy. However, this addition of peptides will hinder the pharmacological properties of the cyanine. In contrast, here with 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)- 1 , 1 -dimethyl-2-((E)-2-((E)-3 -((E)-2-( 1 , 1 ,3 -trimethyl- 1 ,3 -dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium has intrinsic chemical properties to be retained intratumorally. The novelty of this invention is the chemical structure is kept intact without the addition of targeting groups since this is a highly tumor-retained cyanine structure.

[0060] Many highly potent drugs against cancer in preclinical and early clinical research are discarded or discontinued from the clinical trials because they showed poor pharmacokinetics profiles, such as low oral bioavailability, and severe toxicity issues. The proposal is to use those discarded or discontinued drugs for intratumoral administration through a drug-delivering device. Herein a list of highly promising cancer drugs that showed strong anticancer potential but were found to have issues with their pharmacokinetics (absorption, distribution, metabolism, and excretion), leading to challenges in clinical use: Tivantinib (ARQ 197), Irinotecan, Sorafenib, Sorafenib Analog XL999, BAY 43-9006 (Preclinical Sorafenib Derivative), Paclitaxel (Taxol), Venetoclax (Venclexta), Vismodegib (Erivedge), Dasatinib (Sprycel), Epothilones A and B (Natural Epothilones), Bryostatin-1, Flavopiridol (Alvocidib), Tanespimycin (17-AAG), XL 184 (Preclinical Cabozantinib Analog), PR-104, LY293111, DMXAA (Vadimezan), Marizomib (NPI-0052), Epothilone B Derivatives, Obatoclax, Bexarotene Analog (RXR Agonist), SNS-032, IPL 504 (Retaspimycin), XL281, and GRN163L (Imetelstat Precursor). These drugs demonstrate how pharmacokinetic challenges can limit the efficacy or safety of otherwise highly potent anticancer agents. Many of these issues can be addressed with the intratumoral injection methods disclosed herein.

[0061] The new method includes delivering this drug on the pathological side (intratumorally) under proven controlled drug-releasing conditions. This is done under a controlled drug-releasing device. The drug-releasing conditions are important for appropriate retention in the tumor, such as pressure, injection rate (speed of injection), total time of injection, diameter, and length of the drug-releasing device. These factors are important since inappropriate values on these injection conditions can result in the rupture of the tumor tissue and leakage of the drug. Therefore, this process is not only an empiric direct injection of the drug. In contrast, the drug injection can be accomplished under the range of conditions disclosed here. This is a new and non-obvious idea.

[0062] Herein we discussed the speed of injection or flow rate to maximize the perfusion or distribution of the drug in the tumor, minimize the leakage from the tumor and avoid tumor rupture during the intratumoral injection.

[0063] The speed of injection is also known as flow rate or injection rate. Maximizing drug distribution in a tumor while minimizing leakage and avoiding mechanical rupture during an intratumoral injection is a complex process influenced by several factors. These include tumor permeability, interstitial pressure, fluid dynamics, and tissue elasticity. The ideal injection flow rate should balance uniform drug perfusion without exceeding the tumor’s mechanical tolerance.

[0064] Factors Influencing Optimal Injection Speed / Flow Rate: 1) Tumor Interstitial Fluid Pressure (IFP): Tumors typically have elevated interstitial pressure (10-40 mmHg). A flow rate too high will increase pressure and promote leakage or rupture. 2) Tumor Type and Composition: Soft or necrotic tumors allow for easier fluid penetration, whereas fibrotic tumors resist fluid infiltration and require slower, steady injection. 3) Capsular Integrity: Tumors with intact fibrous capsules are prone to rupture under high pressure, requiring lower injection speeds. 4) Viscosity of the Injected Drug: Higher-viscosity drugs may require slower injection to ensure uniform distribution without excessive pressure.

[0065] Optimal Injection Flow Rate Estimates. To avoid tumor rupture and maximize intratumoral drug perfusion, slow to moderate flow rates should be used. General estimates are as follows: 1) Small Tumors (0.5-1 g): Flow rates of 0.1-0.5 mL per minute are often sufficient for even drug distribution without leakage or rupture. 2) Medium Tumors (1-10 g): Flow rates of 0.2-1.0 mL per minute balance drug distribution and minimize mechanical stress on the tissue. 3) Large Tumors (>10 g): Flow rates of 0.5-2.0 mL per minute may be appropriate for larger tumors, but pressure monitoring is critical to prevent excessive buildup.

[0066] Best Practices for Controlled Intratumoral Injection. 1) Fractionated or Pulsed Injections: Dividing the injection into smaller, slower pulses allows pressure dissipation and reduces the risk of leakage or rupture. 2) Real-Time Pressure Monitoring: Monitoring internal tumor pressure during the injection helps ensure it stays below critical thresholds to prevent tissue damage. 3) Image Guidance: Using ultrasound or MRI can help visualize drug distribution in real-time and ensure complete tumor perfusion without over-injection. 4) Pre-inj ection Aspiration: Light aspiration before injection may reduce interstitial pressure and minimize leakage.

[0067] A slow, controlled flow rate (typically 0.1-1.0 mL per minute, depending on tumor size and type) is optimal for maximizing drug distribution without causing mechanical rupture. Individualized adjustments based on tumor properties and real-time pressure monitoring are essential to achieve effective and safe intratumoral drug delivery.

[0068] High-speed injection that breaks the tumor may release cancer cells into surrounding tissues, increasing the risk of local invasion or metastasis. This must be avoided. Careful monitoring and control are essential. Volume-to- Speed Balance: The injection speed should be balanced with the injected volume to prevent over-pressurization, which could lead to complications such as tissue necrosis or inflammation. While the exact injection speed for breaking a tumor depends on tumor-specific characteristics, injection speeds of 5-10 mL per minute or higher are generally enough for mechanical rupture.

[0069] Herein is disclosed the estimated volume of injection required to rupture the tumor. To avoid the rupture of the tumor the volume of injection utilized is lower than the estimated threshold for rupture. The exact volume of injection required to break or disrupt a tumor per gram or size of tumor tissue is not universally defined because it depends on multiple variables, such as: 1) Tumor Type and Composition: Soft, necrotic, or less fibrous tumors will require smaller injection volumes compared to dense, fibrotic, or highly cellular tumors. 2) Tumor Size and Shape: Larger tumors may require proportionally greater injection volumes due to increased tissue mass and internal structural integrity. 3) Capsular Integrity: Tumors with well-defined capsules (often seen in benign tumors) are more resistant to disruption and may require higher volumes or pressures. 4) Interstitial Pressure: Tumors typically have high interstitial fluid pressure, which may resist the infiltration of injected fluid, requiring larger volumes to overcome this pressure. The standardized values for the volume required per gram of tumor tissue to induce mechanical disruption range from 0.5 to 2 mL per gram of tumor tissue, depending on the tissue’s mechanical properties and elasticity. In this invention, injected volumes should be below 0.5 mL per gram of tissue. More specifically, a 10-20% of the tumor's total volume can be used for optimal drug distribution or permeation without mechanical rupture.

[0070] While high-volume injections can disrupt tumors, excessive fluid administration carries risks, such as tumor leakage, cell dissemination, and the spread of malignant cells to nearby tissues.

[0071] Due to the variability in tumor types and limited standardized data, estimating the precise volume of injection per gram or size of tumor tissue requires case-specific evaluation. For experimental or therapeutic contexts, pilot studies and real-time monitoring of fluid dynamics are essential to prevent over-injection and potential complications.

[0072] Herein are the estimated injection times for different tumor sizes at a flow rate of 1 mL per minute: 1) Small Tumor (0.5 g): For 0.1 mL per gram is 0.05 minutes (3 seconds) or for 0.2 mLper gram is 0.1 minutes (6 seconds). 2) Medium Tumor (1 g): For 0.1 mL per gram is 0.1 minutes (6 seconds) or for 0.2 mL per gram is 0.2 minutes (12 seconds). 3) Large Tumor (50 g): For 0.1 mL per gram is 5.0 minutes or for 0.2 mL per gram is 10.0 minutes. These times represent the duration required to inject the calculated volume for each tumor size. For smaller tumors, the injection times are very short, while larger tumors require significantly longer times to administer the same volume per gram.

[0073] Herein are the estimated injection times for different tumor sizes at a flow rate of 0.1 mL per minute: 1) Small Tumor (0.5 g): For 0.1 mL per gram is 0.5 minutes (30 seconds) or for 0.2 mL per gram is 1.0 minute. 2) Medium Tumor (1 g): For 0.1 mL per gram is 1.0 minutes or for 0.2 mL per gram is 2.0 minutes. 3) Large Tumor (50 g): For 0.1 mL per gram is 50.0 minutes or for 0.2 mL per gram is 100.0 minutes. These times represent the duration required to safely inject the estimated volume without causing mechanical rupture. For larger tumors, significantly longer times are needed to ensure uniform distribution and avoid excessive pressure buildup.

[0074] Herein the approximate pressure required to break or disrupt a tumor is considered. The fluid pressure should be kept below the rupture pressure. Fluid pressures exceeding 150-200 mmHg may be sufficient to disrupt or cause extravasation (leakage from blood vessels or lymphatic vessels) in some tumors. However, solid or fibrotic tumors may require even higher pressures for mechanical rupture or disintegration of their structure. In clinical practice, attempting to disrupt or rupture a tumor mechanically (e.g., through high-pressure injection or trauma) is generally avoided due to the risk of tumor cell dissemination, metastasis, or local inflammation. For malignant tumors, rupturing the mass could allow cancer cells to escape into surrounding tissues or body cavities, increasing the risk of spread. This must be avoided.Additional Definitions

[0075] The following definitions or interpretations of technical terms will be used throughout the present disclosure. The technical terms used herein are generally to be given the meaning commonly applied to them in the pertinent art of robotics, cancer biology, molecular biology, and surgery. All the following term definitions apply to the complete content of this application

[0076] To facilitate the understanding of this disclosure, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present disclosure. The use of the word “a” or “an” when used in conjunctionwith the term “comprising” in the claims and / or specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0077] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. In embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of’ or “consisting of.” As used herein, the phrase “consisting essentially of’ requires the specified integer(s) or steps as well as those that do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the recited integer (e.g., a feature, an element, a characteristic, a property, a method / process step or a limitation) or group of integers (eg., feature(s), element(s), characteristic(s), propertie(s), method / process steps or limitation(s)) only.

[0078] The term “or combinations thereof’ as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof’ is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0079] As used herein, words of approximation such as, without limitation, “about,” “substantial” or “substantially” refers to a condition that when so modified is understood to not necessarily be absolute or perfect but would be considered close enough to those of ordinary skill in the art to warrant designating the condition as being present. The extent to which the description may vary will depend on how great a change can be instituted and still have one of ordinary skill in the art recognize the modified feature as still having the required characteristics and capabilities of the unmodified feature. In general, but subject to the preceding discussion, a numerical value herein that is modified by a word of approximation such as “about” may vary from the stated value by at least ±1, 2, 3, 4, 5, 6, 7, 10, 12 or 15%.

[0080] NIR: Near-infrared light, namely light within the 650-2300 nm wavelength. There are multiple therapeutic windows: 1) first window (NIR-I), approximately from 650 nm to 950 nm, 2) second window (NIR-II) approximately from 1000 nm to 1350 nm, 3) third window (NIR-III) approximately from 1500 nm to 1800 nm, and 4) the emerging NIR-IV Window (2100-2300 nm). The light source can be a continuous wave (CW), pulsed laser, a pulsed light-emitting diode (LED), or a continuous wave LED.

[0081] Miniaturized: a component with reduced physical size on the millimeter-scale, lightweight construction, low-profile integrations into 3-10 mm diameter instruments. Some examples include, but are not limited to, compact motor and transmission systems, micro-scale sensors and actuators, micro-gears or flexure-based mechanisms, microfluidic drug pumps, and thin optical fiber channels for NIR light delivery.

[0082] Robotic Mechanism: a device that includes, but is not limited to, an actuator, a sensor, a control system, and is programmable. This mechanism’s functionality could precisely control needle insertion depth, adjust the angle of deployment, control multi-port drug dispersion, position and stabilize NIR optical fibers, regulate infusion rates, and respond to pressure changes in real time. The following include some, but not all, examples of miniaturized robotic mechanisms: a micro-actuated needle deployment that uses a small motor to advance the needle in sub-millimeter increments and has a built-in force sensor that stops advancement if resistance spikes; a steerable microcatheter tip with a tiny actuator that allows the tip to bend inside tissue; an integrated micropump system that has an embedded microfluidic pump; a NIR light steering device using small internal mirrors or rotating fiber ports.

[0083] Gas: a substance that fills a whole area. Some examples include, but are not limited to, carbon dioxide, nitrogen, oxygen, and combinations of said gases.EXAMPLES

[0084] The following examples are included to demonstrate preferred embodiments of the disclosure. It should be appreciated that many changes can be made in the specific embodiments which are disclosed and still obtain similar results without departing from the scope of the disclosure.EXAMPLE 1 - Evidence of high tumor retention molecule (aminocyanine)

[0085] FIG. 2. Provides the chemical structure and evidence for the high tumor retention of aminocyanine molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. The chemical structure of this aminocyanine molecule is shown in FIG. 2A. In panel FIG. 2B mice with pancreatic cancer tumors implanted subcutaneously on the right-leg are shown. It is shown the tumor was injected with aminocyanine intratumorally. The green-dark color selectively localized on the tumor corresponds to the aminocyanine color. The aminocyanine can be observed by human sight. This is one of the advantages of this invention, the antitumoral drug can be directly seen by the human eye when it is delivered and retained in the tumor. No sophisticated imaging instrumentation is needed to visualize the compound's retention. The images correspond to 1 day after treatment. See that the aminocyanine is highly retained in the tumor after day (1 d). Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size ~100 mm3~ 0.1 g. The aminocyanine delays the tumor growth. In FIG.2D Lipinski’s rule of five property calculator shows the molecule has two violations of the criteria.EXAMPLE 2 - Evidence of therapeutic efficacy of aminocyanine molecule in pancreatic tumors.

[0086] FIG. 3. Provides evidence of the therapeutic efficacy of intratumorally injected molecule 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-(l,l,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium against pancreatic cancer tumors implanted in nude mice. The molecule is injected at 7.5 mM concentration in a solution containing a mixture of 5% DMSO in PBS buffer. The control is 5% DMSO in PBS. The total injected volume was 20 pL. Injection volume ~ 0.2mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size —100 mm3~ 0.1 g. The molecule was injected at day 1, day 3 and day 8.EXAMPLE 3 - Evidence of high tumor retention of aminocyanine molecule for long term (days) and short term (hours).

[0087] FIG. 5. Shows evidence of intratumoral retention of aminocyanine molecule 2 days after treatment. The molecule is 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2-((E)-3-((E)-2-( 1 , 1 ,3 -trimethyl- 1 ,3 -dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex- 1 -en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. The mice were implanted with pancreatic cancer tumors subcutaneously on the right-leg. In FIG. 5A The tumors were injected with molecule intratumorally. In FIG. 5B the tumor was injected with PBS solution (control). The green-dark color corresponds to the aminocyanine color. The aminocyanine can be observed by human sight (This is one of the advantages of this invention). No need to use sophisticated imaging instrumentation. The images correspond to 2 days after the treatment. See that the molecule is highly retained in the tumor after 2 days. The molecule delays the tumor growth. Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. The molecule is injected at 7.5 mM concentration in a solution containing a mixture of 5% DMSO in PBS buffer. The control is 5% DMSO in PBS.

[0088] FIG. 6 provides evidence that the aminocyanine molecule is retained in the tumor even 7 days after the injection and the growth of the tumor is delayed. It shows mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. The injected aminocyanine molecule is 3-(6-((6-amm oniohexyl )amino)-6-oxohexyl)-l , 1 -dimethyl-2-((E)-2-((E)-3-((E)-2-(l , 1 ,3-trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)-lH-benzo[e]indol-3-ium. In FIG. 6Athe tumor is injected with the aminocyanine intratumorally. In FIG. 6B the tumor is injected with PBS solution (control). The green-dark color corresponds to the aminocyanine color. The aminocyanine can be observed by human sight (This is one of the advantages of this invention). There is no need to use sophisticated imaging instrumentation to observe the cyanine. The images correspond to 7 days after the first treatment. See that the aminocyanine is highly retained in the tumor after several days (7 d). The aminocyanine delaysthe tumor growth. Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min.

[0089] FIG. 7 provides evidence that the aminocyanine is highly retained in the tumor at 1 h after injection through fluorescence detection. The mice were implanted with pancreatic cancer tumors subcutaneously on the right-leg. In FIG. 7A the tumor is injected with aminocyanine intratum orally. In FIG. 7B the tumor is injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 1 h after treatment. Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size —100 mm3~ 0.1 g.

[0090] FIG. 8 provides evidence that the aminocyanine is highly retained in the tumor at 24 h after injection through fluorescence detection. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. In FIG. 8 A the tumor is injected with aminocyanine intratum orally. In FIG. 8B the tumor is injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 24 h after treatment. Inj ection volume -0.2 mL per gram of tumor. Inj ection rate: 4 pL / s = 0.24 mL / min. Tumor size ~100 mm3~ 0.1 g.

[0091] FIG. 9 provides evidence that the aminocyanine is highly retained in the tumor at 48 h after injection through fluorescence detection. Mice with pancreatic cancer tumors implanted subcutaneously on the right-leg. In FIG. 9A the tumor is injected with aminocyanine intratum orally. In FIG. 9B the tumor is injected with PBS solution (control). The color in the tumor area corresponds to the fluorescence emission from aminocyanine. The images correspond to 48 h after treatment. See that the aminocyanine is highly retained in the tumor after 1 h. Injection volume ~ 0.2 mL per gram of tumor. Injection rate: 4 pL / s = 0.24 mL / min. Tumor size ~100 mm3~ 0.1 g.EXAMPLE 4 - Evidence of aminocyanine leakage when the tumor is ruptured under wrong injecting conditions.

[0092] FIG. 10 provides evidence that the molecule can leak outside the tumor when is not appropriately injected under unoptimized conditions of dose per mass of tumor, flow rate, volume, and / or fluid pressure. It illustrates the importance of the parameters and use of medical device (e.g, syringe pump) for better control to maximize retention and avoid tumor rupture. Mice withpancreatic cancer tumors implanted subcutaneously on the right leg were used. The tumor was injected with aminocyanine intratum orally. The color in the tumor area corresponds to the fluorescence emission from aminocyanine. Injection volume ~ 0.4 mL per gram of tumor. Injection rate: 8 pL / s = 0.5 mL / min.EXAMPLE 5 - Technical Specifications for Intratumoral Drug Delivery in Pancreatic Cancer Using Laparoscopy

[0093] Laparoscopic intratumoral drug delivery is an advanced technique used to target pancreatic tumors with precise drug administration. This approach involves introducing a thin catheter with a needle tip directly into the tumor under laparoscopic guidance. Below are the technical specifications for performing this procedure:1. Laparoscopic Systemi. Laparoscope: A high-definition (HD) or 4K laparoscope with a diameter of 5-10 mm and a 30-degree or 45-degree viewing angle is recommended to provide optimal visualization of the pancreas and surrounding tissues.ii. Ports:a. Access Ports: Typically, 3-4 laparoscopic ports (5-12 mm) are used. One port is designated for the laparoscope, and the others allow for instrument manipulation. b. Catheter Port: A dedicated port (typically 5 mm) is used for inserting the catheter and needle system.iii. Illumination: LED or fiber-optic lighting for clear visualization of deep pancreatic tissue. iv. Insufflation System: Carbon dioxide insufflation is used to maintain pneumoperitoneum at a pressure of 10-15 mmHg to enhance visibility and create working space.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer diameter: 1-2 mm for minimal invasiveness and ease of tissue penetration.b. Length: 20-30 cm to accommodate intratumoral insertion in various tumor locations within the pancreas.c. Material: Biocompatible polymer, preferably PTFE (polytetrafluoroethylene), for flexibility and durability.ii. Needle Tip:a. Gauge: 18-22G needle to ensure precise tumor penetration and minimize tissue trauma.b. Length: 10-15 mm to ensure deep tumor penetration without breaching the tumor capsule.c. Bevel design: A short, angled bevel ensures smooth insertion into dense pancreatic tissue.iii. Injection System: A syringe pump or manual injection system connected to the catheter controls the injection rate, ensuring precise drug delivery. Flow rates are typically adjustable between 0.1-0.5 mL per minute to prevent overpressurization and tissue rupture.3. Procedure Protocoli. Patient Positioning: The patient is placed in a supine or modified lateral decubitus position to optimize access to the pancreas.ii. Laparoscopic Access: A laparoscope is inserted through the primary port, and secondary ports are established to access the pancreatic tumor.iii. Tumor Identification: Under visual and, if available, laparoscopic ultrasound (LUS) guidance, the tumor is localized.iv. Catheter Insertion: The thin catheter with the needle is inserted through the dedicated port and advanced to the tumor under direct visualization.v. Needle Placement: The needle is carefully inserted into the tumor, ensuring penetration without breaching the opposite tumor boundary or capsule.vi. Drug Delivery: The drug is injected at a controlled rate (e.g., 0.1-0.5 mL per minute) to ensure uniform distribution and avoid tumor rupture.vii. Needle Withdrawal: The needle is slowly withdrawn to minimize leakage or backflow of the drug.viii. Site Inspection: The tumor site is inspected for signs of leakage or tissue damage before port closure.4. Safety Considerationsi. Pressure Monitoring: Real-time pressure monitoring may be employed to avoid excessive intratumoral pressure.ii. Leakage Control: Tumor encapsulation or gentle manual pressure over the tumor site may help minimize drug leakage.iii. Complication Management: Be prepared for potential complications such as minor bleeding, drug leakage, or pancreatic inflammation.iv. Imaging Confirmation: Intraoperative imaging may be used to confirm drug distribution within the tumor.5. Post-Procedure Carei. Monitor for signs of pancreatic inflammation, pain, or drug-related adverse effects. ii. Follow-up imaging may be conducted to assess tumor response to the intratumoral drug delivery.

[0094] This technique provides a minimally invasive approach to precise drug delivery in pancreatic cancer, enhancing therapeutic efficacy while minimizing systemic drug exposure.EXAMPLE 6 - Technical Specifications for Intratumoral Drug Delivery in Lung Cancer Using Laparoscopy (Thoracoscopy).

[0095] Intratumoral drug delivery in lung cancer using laparoscopy, or more specifically thoracoscopy (a form of video-assisted thoracoscopic surgery or VATS), is a precise, minimally invasive technique. It involves using a thoracoscope to guide a thin catheter with a needle to thelung tumor for localized drug administration. Below are the detailed technical specifications for performing this procedure:1. Thoracoscopic (VATS) Systemi. Thoracoscope Specifications:a. Diameter: 5-10 mm, depending on the surgical access required.b. Viewing Angle: 30° or 45° angles are preferred for enhanced visualization of lung tissue and tumor boundaries.c. Resolution: High-definition (HD) or 4K visualization for clear identification of lung tumor tissue and vasculature.ii. Access Ports:a. Atypical VATS procedure uses 2-3 ports (5-12 mm in diameter).b. One port is dedicated to the thoracoscope, and another port is reserved for catheter insertion and manipulation.iii. Insufflation and Lung Collapse: A single-lung ventilation technique is used to collapse the lung on the affected side, creating space for manipulation and improved tumor access.2. Catheter and Needle Systemi. Catheter Design:a. Outer Diameter: 1-2 mm to minimize invasiveness and ensure flexibility for precise positioning.b. Length: 20-30 cm to ensure sufficient length for deep tumor access.c. Material: Biocompatible polymer (e.g., PTFE or silicone) for durability and smooth insertion.ii. Needle Tip:a. Gauge: 18-22G, which allows for minimal tissue trauma while penetrating the tumor.b. Length: 10-15 mm for deep tumor penetration without risking puncture of the pleural surface or opposite tumor wall.c. Bevel: A short, sharp bevel for smooth penetration through dense tumor tissue and fibrosis.iii. Injection System:a. Syringe pump or manual injection system for controlling the injection rate. b. Adjustable flow rates between 0.1-0.5 mb per minute to optimize drug distribution and prevent tumor rupture.3. Procedural Stepsi. Patient Positioning: The patient is placed in a lateral decubitus position with the affected side up, optimizing access to the tumor.ii. Thoracoscopic Access: Port sites are created, and the thoracoscope is inserted through the primary port for visualization of the lung and tumor.iii. Tumor Localization: The tumor is identified using thoracoscopic visualization. In some cases, intraoperative ultrasound may be used to guide accurate catheter placement within the tumor.iv. Catheter Insertion: A thin catheter with a needle at its tip is inserted through a dedicated port. It is carefully advanced to the tumor site under direct visualization.v. Needle Insertion: The needle is inserted into the tumor, ensuring sufficient depth for intratumoral drug delivery while avoiding penetration of the opposite tumor wall. vi. Drug Injection: The drug is injected at a controlled rate (0.1-0.5 mL per minute) to promote uniform distribution within the tumor and prevent overpressurization.vii. Needle Withdrawal: The needle is slowly withdrawn, and manual compression may be applied to minimize drug leakage from the injection site.viii. Inspection: The injection site is inspected for signs of leakage, bleeding, or tissue damage. The pleural cavity is assessed for any complications before removing the thoracoscope and closing the ports.4. Safety Considerationsi. Pressure Monitoring: Monitoring the intratumoral and pleural pressure during injection can prevent excessive pressure buildup and tissue rupture.ii. Leakage Prevention: Slow, steady injection and proper needle placement help reduce the risk of drug leakage into the pleural cavity.iii. Bleeding Control: Careful needle insertion and withdrawal help minimize trauma to surrounding lung vasculature.iv. Complication Management: Be prepared for potential complications, such as pneumothorax, bleeding, or drug leakage, which may require drainage or additional intervention.5. Post-Procedure Carei. Monitoring: Continuous monitoring for signs of respiratory distress, pleural effusion, or pneumothorax.ii. Imaging: Postoperative chest X-ray or CT scan to assess drug distribution and rule out complications.iii. Pain Management: Thoracic epidural or intercostal nerve blocks may be used to manage post-thoracoscopy pain.

[0096] This technique allows for precise intratumoral drug delivery in lung cancer, enhancing local drug concentration and minimizing systemic exposure. Careful control of injection rate and needle placement, along with real-time visualization, ensures safe and effective treatment delivery.EXAMPLE 7 - Technical Specifications for Intratumoral Drug Delivery in Liver Cancer Using Laparoscopy

[0097] Intratumoral drug delivery in liver cancer using laparoscopy is a minimally invasive technique that enables direct, localized drug administration into hepatic tumors. This approachenhances therapeutic efficacy while minimizing systemic toxicity. The procedure involves using a laparoscope to guide a thin catheter with a needle to the liver tumor for precise drug injection. Below are the technical specifications for performing this technique:1. Laparoscopic Systemi. Laparoscope Specifications:a. Diameter: 5-10 mm for optimal visualization and maneuverability.b. Viewing Angle: 30° or 45° to provide enhanced depth perception when navigating liver tissue.c. Resolution: HD or 4K visualization for clear identification of liver tumor margins and vasculature.ii. Access Ports:a. Typically, 3-4 laparoscopic ports (5-12 mm) are used.b. One port is designated for the laparoscope, another for catheter insertion, and additional ports for instrument manipulation if needed.iii. Insufflation System:a. Carbon dioxide (CO2) insufflation is used to create pneumoperitoneum at 10-14 mmHg, allowing for optimal liver exposure and reducing diaphragmatic movement.iv. Liver Retraction:a. A laparoscopic liver retractor may be used to lift and stabilize the liver for better access to deep-seated tumors.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1-2 mm, ensuring minimal invasiveness and flexibility for precise positioning.b. Length: 20-30 cm, allowing access to deep or posterior liver tumors.c. Material: Biocompatible polymer (PTFE or silicone) for durability and smooth tissue penetration.ii. Needle Tip:a. Gauge: 18-22G to allow deep tumor penetration while minimizing tissue trauma. b. Length: 10-15 mm, providing sufficient depth for intratumoral delivery without perforating the tumor capsule.c. Bevel Design: Short, angled bevel to optimize penetration into fibrotic or dense liver tumors.iii. Injection System:a. Syringe pump or manual injection system to regulate drug delivery at controlled flow rates.b. Adjustable flow rate between 0.1-0.5 mb per minute to ensure optimal perfusion while preventing tissue rupture or drug leakage.. Procedural Stepsi. Patient Positioning:a. The patient is placed in the supine or reverse Trendelenburg position to allow the liver to shift downward, improving exposure.ii. Laparoscopic Access:a. The primary laparoscope is inserted, and secondary ports are positioned for instrument and catheter manipulation.iii. Tumor Localization:a. The tumor is identified using laparoscopic visualization, and intraoperative ultrasound (IOUS) may be used to guide catheter placement within the tumor. iv. Catheter Insertion:a. A thin catheter with a needle tip is introduced through a dedicated port and guided towards the tumor under direct visualization.v. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring penetration into the central mass while avoiding excessive depth that could lead to leakage into adjacent liver tissue.vi. Drug Injection:a. The drug is administered at a controlled rate of 0.1-0.5 mL per minute to allow uniform intratumoral distribution.b. Slow injection prevents overpressurization and minimizes backflow or leakage. vii. Needle Withdrawal:a. The needle is slowly withdrawn, with minimal disturbance to the tissue to prevent drug escape.b. Gentle manual compression over the injection site may be applied to reduce leakage.viii. Site Inspection:a. The liver surface is inspected for any signs of bleeding, leakage, or injury before port closure.4. Safety Considerationsi. Pressure Monitoring:a. Real-time monitoring of intratumoral pressure can help prevent excessive pressure buildup and tumor rupture.ii. Leakage Prevention:a. Proper needle positioning and slow injection rates reduce the risk of drug leakage into surrounding liver tissue or the peritoneal cavity.iii. Bleeding Control:a. The high vascularity of the liver necessitates careful insertion and withdrawal of the needle to avoid bleeding.b. Hemostatic agents may be applied in case of minor bleeding.iv. Complication Management:a. Be prepared for potential complications, such as capsular rupture, vascular injury, or bile duct leakage, which may require additional interventions.v. Imaging Confirmation:a. Intraoperative ultrasound (IOUS) or contrast-enhanced imaging may be used postinjection to confirm adequate drug distribution within the tumor.. Post-Procedure Carei. Monitoring:a. Patients should be monitored for signs of liver dysfunction, bleeding, or peritoneal irritation postoperatively.ii. Imaging Follow-Up:a. CT or MRI scans may be performed to assess drug retention within the tumor and detect any complications.iii. Pain Management:a. Local anesthetics or systemic analgesia may be required to manage post- laparoscopic pain.

[0098] Laparoscopic intratumoral drug delivery in liver cancer provides a targeted, minimally invasive approach for localized chemotherapy, immunotherapy, or experimental treatments. This method allows precise drug delivery while minimizing systemic exposure and complications. Careful control of injection speed, needle placement, and pressure monitoring ensures safe and effective treatment administration.EXAMPLE 8 - Technical Specifications for Intratumoral Drug Delivery in Ovarian Cancer Using Laparoscopy

[0099] Laparoscopic intratumoral drug delivery in ovarian cancer is a minimally invasive technique that allows direct administration of therapeutic agents into ovarian tumors. This approach enhances local drug concentration while reducing systemic side effects. The procedure involves using a laparoscope to guide a thin catheter with a needle tip to the ovarian tumor for precise drug injection. Below are the technical specifications for performing this technique.1. Laparoscopic Systemi. Laparoscope Specifications:a. Diameter: 5-10 mm for optimal maneuverability and visualization.b. Viewing Angle: 30° or 45° to allow enhanced visualization of the ovaries and pelvic structures.c. Resolution: HD or 4K for clear identification of ovarian tumors, vascular structures, and surrounding tissues.ii. Access Ports:a. Typically, 3-4 laparoscopic ports (5-12 mm) are used.b. One port is dedicated to the laparoscope, one for the catheter insertion, and others for instrument manipulation if necessary.iii. Insufflation System:a. Carbon dioxide (CO2) insufflation at 12-15 mmHg to create pneumoperitoneum for optimal visualization and space for manipulation.iv. Ovary Stabilization:a. Laparoscopic graspers may be used to gently stabilize the ovary and expose the tumor for precise catheter positioning.2. Catheter and Needle Systemv. Catheter Specifications:a. Outer Diameter: 1-2 mm for minimal invasiveness and flexibility in positioning. b. Length: 20-30 cm to accommodate deep-seated ovarian tumors.c. Material: Biocompatible polymer (PTFE or silicone) to ensure smooth insertion and durability.vi. Needle Tip:a. Gauge: 18-22G, allowing deep tumor penetration while minimizing tissue trauma. b. Length: 10-15 mm to ensure adequate intratumoral drug delivery without puncturing the opposite tumor wall.c. Bevel Design: Short, angled bevel to optimize penetration into solid ovarian tumors.vii. Injection System:a. Syringe pump or manual injection system to regulate drug delivery at controlled flow rates.b. Adjustable flow rate between 0.1-0.5 mb per minute to optimize perfusion while preventing leakage or tissue rupture.3. Procedural Stepsi. Patient Positioning:a. The patient is placed in the lithotomy or Trendelenburg position to enhance pelvic exposure.ii. Laparoscopic Access:a. The primary laparoscope is inserted, and secondary ports are placed for catheter insertion and tissue manipulation.iii. Tumor Localization:a. The ovarian tumor is identified using laparoscopic visualization, and intraoperative ultrasound (IOUS) may be used for precise localization.iv. Catheter Insertion:a. A thin catheter with a needle tip is inserted through a dedicated port and guided towards the tumor under direct visualization.v. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring deep penetration without breaching the ovarian capsule.vi. Drug Injection:a. The drug is administered at a controlled rate of 0.1-0.5 mL per minute to allow uniform intratumoral distribution.b. Slow injection prevents overpressurization and minimizes backflow or leakage. vii. Needle Withdrawal:a. The needle is slowly withdrawn, and manual compression may be applied to reduce drug leakage.viii. Site Inspection:a. The ovarian surface is inspected for signs of bleeding, leakage, or tissue damage before closing the laparoscopic ports.4. Safety Considerationsi. Pressure Monitoring:a. Monitoring intratumoral pressure ensures controlled drug delivery and prevents mechanical rupture of the tumor.ii. Leakage Prevention:a. Proper needle positioning and slow injection rates help minimize drug leakage into the peritoneal cavity.iii. Bleeding Control:a. The high vascularity of ovarian tumors requires careful needle insertion to prevent hemorrhage.b. Hemostatic agents may be applied if minor bleeding occurs.iv. Complication Management:a. Preparedness for complications such as capsular rupture, peritoneal irritation, or vascular injury, which may require additional intervention.v. Imaging Confirmation:a. Intraoperative ultrasound (IOUS) or contrast-enhanced imaging may be used postinjection to confirm adequate drug distribution within the tumor.5. Post-Procedure Carei. Monitoring:a. Patients should be monitored for signs of bleeding, peritoneal irritation, or ovarian dysfunction postoperatively.ii. Imaging Follow-Up:a. Ultrasound, CT, or MRI scans may be performed to assess drug retention within the tumor and detect any complications.iii. Pain Management:a. Local anesthetics or systemic analgesia may be required to manage post- laparoscopic pain.

[0100] Laparoscopic intratumoral drug delivery in ovarian cancer provides a targeted, minimally invasive method for localized chemotherapy, immunotherapy, or experimentaltreatments. This approach allows precise drug administration while reducing systemic toxicity and complications. Careful control of injection speed, needle placement, and pressure monitoring ensures safe and effective treatment administration.EXAMPLE 9 - Technical Specifications for Intratumoral Drug Delivery in Colorectal Cancer Using Endoscopy

[0101] Endoscopic intratumoral drug delivery is a minimally invasive technique that allows for the precise administration of therapeutic agents directly into colorectal tumors. This approach enhances drug concentration at the tumor site while reducing systemic side effects. The procedure involves using a flexible endoscope to guide a thin catheter with a needle tip for accurate drug injection into the tumor. Below are the technical specifications for this method.1. Endoscopic Systemi. Endoscope Type:a. High-definition (HD) or 4K colonoscope for optimal visualization of colorectal tumors.b. Outer Diameter: 10-14 mm to ensure compatibility with standard colorectal endoscopy procedures.c. Working Channel Diameter: > 3.2 mm to accommodate catheter insertion. d. Working Length: 120-170 cm to reach tumors in various locations along the colon and rectum.e. Angulation: Up to 180° for flexible maneuverability in confined spaces. ii. Imaging Modalities:a. White-light endoscopy (WLE) for standard visualization.b. Narrow-band imaging (NBI) or chromoendoscopy for enhanced tumor contrast. c. Endoscopic ultrasound (EUS) for depth assessment and precise needle guidance.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.8-2.8 mm for seamless insertion through the working channel. b. Length: 200-250 cm to reach distal colorectal tumors.c. Material: Biocompatible polymer (PTFE or silicone) for smooth passage and minimal tissue irritation.ii. Needle Tip:a. Gauge: 22-25G for precise penetration with minimal tissue damage.b. Length: 5-15 mm to ensure accurate intratumoral placement.c. Bevel Design: Short, angled bevel for controlled insertion into the tumor mass. iii. Injection System:a. Syringe pump or manual injection system for controlled drug delivery.b. Flow rate adjustable between 0.05-0.5 mL per minute to optimize drug distribution and prevent backflow.3. Procedural Stepsi. Patient Preparation:a. Standard bowel preparation with laxatives before the procedure.b. Sedation or anesthesia depending on the patient's condition and tumor location. ii. Endoscope Insertion:a. The endoscope is introduced transanally and advanced to the tumor site under realtime visualization.iii. Tumor Localization:a. White-light endoscopy, NBT, or chromoendoscopy is used to identify the tumor. b. Endoscopic ultrasound (EUS) may assist in assessing tumor depth and guiding the needle placement.iv. Catheter Insertion:a. A thin catheter with a needle tip is passed through the endoscope’s working channel and positioned at the tumor site.v. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring penetration depth without breaching the serosal layer.vi. Drug Injection:a. The drug is administered at a controlled rate of 0.05-0.5 mb per minute to maximize perfusion.b. Slow injection minimizes pressure buildup and prevents drug leakage. vii. Needle Withdrawal:a. The needle is gradually withdrawn, and the injection site is inspected for bleeding or leakage.viii. Final Inspection:a. The tumor site is re-examined to ensure proper drug deposition and rule out complications.4. Safety Considerationsi. Pressure Monitoring:a. Monitoring intratumoral pressure prevents mechanical rupture or drug reflux into adjacent tissue.ii. Leakage Prevention:a. Slow injection rates and precise needle positioning reduce the risk of drug escape into the intestinal lumen.iii. Bleeding Control:a. Due to the vascular nature of colorectal tumors, careful needle placement minimizes hemorrhagic risk.b. Hemostatic clips or coagulation techniques may be used if bleeding occurs. iv. Complication Management:a. Preparedness for complications such as perforation, tumor rupture, or obstruction, which may require immediate intervention.v. Imaging Confirmation:a. Contrast-enhanced endoscopy or EUS may be used post -injection to confirm drug retention within the tumor.5. Post-Procedure Carei. Monitoring:a. Patients should be observed for rectal bleeding, abdominal pain, or perforation signs post-procedure.ii. Follow-Up Imaging:a. CT, MRI, or endoscopic follow-up may be performed to assess drug distribution and treatment efficacy.iii. Pain Management:a. Local anesthetics or mild analgesics may be administered to alleviate postprocedural discomfort.

[0102] Endoscopic intratumoral drug delivery in colorectal cancer provides a precise, minimally invasive approach for targeted chemotherapy, immunotherapy, or experimental treatments. This technique ensures localized drug administration, reducing systemic toxicity andimproving therapeutic outcomes. Proper injection control, needle positioning, and imaging guidance are essential for safe and effective treatment delivery.EXAMPLE 10 - Technical Specifications for Intratumoral Drug Delivery in Head and Neck Cancers Using Endoscopy

[0103] Endoscopic intratumoral drug delivery is a minimally invasive technique designed to precisely administer therapeutic agents directly into tumors of the head and neck region, including cancers of the oropharynx, larynx, hypopharynx, and nasopharynx. This approach enhances drug concentration at the tumor site while minimizing systemic side effects. The procedure involves using a flexible endoscope to guide a thin catheter with a needle tip to inject the drug intratumorally. Below are the technical specifications for this method.1. Endoscopic Systemi. Endoscope Type:a. Flexible nasopharyngoscope or laryngoscope for tumors in the nasopharynx, oropharynx, and larynx.b. Transoral or transnasal rigid endoscope for improved stability in tumors of the oral cavity or hypopharynx.c. Outer Diameter: 3-6 mm for transnasal approaches and 5-10 mm for transoral access.d. Working Channel Diameter: > 2.0 mm to allow passage of the catheter. e. Working Length: 30-60 cm, depending on the tumor location.f. Angulation: Up to 160° to access complex anatomical structures.ii. Imaging Modalities:a. White-light endoscopy (WLE) for standard visualization.b. Narrow-band imaging (NBI) or autofluorescence endoscopy (AFE) to enhance tumor contrast and vascularization assessment.c. Endoscopic ultrasound (EUS) guidance for deep-seated tumors or submucosal lesions.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm for easy maneuverability within the endoscope channel.b. Length: 50-100 cm to allow reach into deep-seated oropharyngeal and laryngeal tumors.c. Material: Flexible, biocompatible polymer (PTFE or silicone) for smooth insertion and minimal irritation.ii. Needle Tip:a. Gauge: 22-27G for precise tissue penetration with minimal trauma.b. Length: 3-10 mm, depending on tumor depth and site.c. Bevel Design: Short, angled bevel for controlled intratumoral placement. iii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate adjustable between 0.05-0.5 mb per minute to prevent tissue rupture and minimize drug leakage.3. Procedural Stepsi. Patient Preparation:a. Topical anesthesia (lidocaine spray) or mild sedation to minimize discomfort. b. Flexible or rigid endoscope insertion through the nasal cavity or mouth, depending on tumor location.ii. Tumor Localization:a. White-light endoscopy, NBT, or AFE is used to visualize the tumor margins. b. Endoscopic ultrasound (EUS) may assist in depth assessment and needle placement.iii. Catheter Insertion:a. A thin catheter with a needle tip is advanced through the working channel of the endoscope toward the tumor site.iv. Needle Placement:a. The needle is precisely inserted into the tumor, ensuring intratumoral penetration without puncturing beyond the tumor margins.v. Drug Injection:a. The therapeutic agent is administered at a controlled flow rate (0.05-0.5 mb per minute) to enhance tumor perfusion and reduce leakage.vi. Needle Withdrawal:a. The needle is slowly withdrawn, and the injection site is checked for drug reflux or bleeding.vii. Final Inspection:a. The tumor area is re-evaluated using endoscopy to ensure successful drug delivery.4. Safety Considerationsi. Pressure Monitoring:a. Real-time monitoring of tissue resistance prevents mechanical rupture or unwanted drug diffusion.ii. Leakage Prevention:a. Proper needle positioning and slow injection rates minimize drug escape into surrounding mucosa.iii. Bleeding Control:a. The head and neck region has high vascularity, so cautery, hemostatic agents, or absorbable gelatin sponges should be available.iv. Complication Management:a. Preparedness for laryngospasm, airway obstruction, or accidental mucosal perforation, which may require emergency intervention.v. Imaging Confirmation:a. EUS or contrast-enhanced imaging may be used post-injection to confirm drug deposition.5. Post-Procedure Carei. Monitoring:a. Patients should be monitored for airway compromise, pain, or swallowing difficulties after the procedure.ii. Follow-Up Imaging:a. MRI, CT, or endoscopic follow-up may be needed to assess drug distribution and treatment response.iii. Pain Management:a. Topical anesthetics, systemic analgesia, or corticosteroids may be used to manage post-procedural discomfort.

[0104] Endoscopic intratumoral drug delivery in head and neck cancer provides a precise, minimally invasive approach for localized chemotherapy, immunotherapy, or experimental treatments. The technique ensures targeted drug administration, reducing systemic exposure while improving therapeutic outcomes. Careful injection control, needle placement, and pressure monitoring are essential for safe and effective treatment delivery in this anatomically complex region.EXAMPLE 11 - Technical Specifications for Tntratumoral Drug Delivery in Bladder Cancer Using Endoscopy

[0105] Intratumoral drug delivery via endoscopic-assisted injection is an advanced technique for treating bladder cancer by administering therapeutic agents directly into tumor tissues. This approach enhances local drug concentration, minimizes systemic toxicity, and improves treatment efficacy. A thin catheter with a needle tip is guided through a cystoscope (bladder endoscope) to precisely inject the drug into the tumor. Below are the technical specifications for this procedure.1. Endoscopic System (Cystoscope Specifications)i. Endoscope Type:a. Rigid cystoscope for stable, high-resolution visualization of bladder tumors. b. Flexible cystoscope for improved maneuverability in cases requiring precise positioning.ii. Outer Diameter:a. 16-22 Fr (5.3-73 mm) for rigid cystoscopes.b. 12—17 Fr (4.0-5.7 mm) for flexible cystoscopes.iii. Working Channel Diameter: > 2.0 mm to accommodate catheter insertion.iv. Working Length: 30-40 cm to reach all bladder wall regions.v. Imaging Modalities:a. White-light cystoscopy (WLC) for standard visualization.b. Narrow-band imaging (NBI) or blue-light cystoscopy (BLC) to enhance tumor contrast and vascular assessment.c. Ultrasound or contrast-enhanced imaging for deep or submucosal tumors.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm for smooth passage through the cystoscope channel. b. Length: 50-100 cm for access to tumors at different bladder wall locations. c. Material: Biocompatible polymer (PTFE or silicone) to ensure flexibility and ease of insertion.ii. Needle Tip:a. Gauge: 22-27G for precise penetration with minimal trauma.b. Length: 3-10 mm, depending on tumor depth.c. Bevel Design: Short, angled bevel for controlled intratumoral placement.iii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate: Adjustable between 0.05-0.5 mL per minute to optimize drug absorption while preventing leakage or tissue rupture.3. Procedural Stepsi. Patient Preparation:a. Bladder emptying via catheterization to improve visualization.b. Local anesthesia or mild sedation for patient comfort.c. Sterile irrigation with saline or contrast solution for better tumor identification. ii. Tumor Localization:a. White-light cystoscopy (WLC), NBI, or BLC is used to visualize and delineate tumor margins.b. Ultrasound guidance may assist in evaluating deeper tumor invasion.iii. Catheter Insertion:a. A thin catheter with a needle tip is inserted through the working channel of the cystoscope and advanced toward the tumor.iv. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring intratumoral penetration without perforating the bladder wall.v. Drug Injection:a. The therapeutic agent is administered at a controlled flow rate (0.05-0.5 mL per minute) to ensure effective intratumoral absorption and prevent reflux into the bladder lumen.vi. Needle Withdrawal:a. The needle is slowly retracted, and the injection site is inspected for bleeding or leakage.vii. Final Inspection:a. The bladder wall is re-evaluated using the cystoscope to confirm proper drug delivery.4. Safety Considerationsi. Pressure Monitoring:a. Ensures the tumor remains intact, avoiding excessive pressure that could rupture the bladder wall.ii. Leakage Prevention:a. Slow injection rates and precise needle placement minimize drug diffusion into the bladder lumen.iii. Bleeding Control:a. The bladder is highly vascularized, so cautery, hemostatic agents, or absorbable gelatin sponges should be available.iv. Complication Management:a. Preparedness for hematuria, bladder irritation, or perforation, which may require medical intervention.v. Imaging Confirmation:a. Ultrasound or contrast cystography may be used post-injection to verify drug retention in the tumor.5. Post-Procedure Carei. Monitoring:a. Patients should be observed for hematuria, dysuria, or bladder discomfort postprocedure.ii. Follow-Up Imaging:a. MRI, CT, or repeat cystoscopy may be performed to assess drug distribution and tumor response.iii. Pain Management:a. Analgesics, antispasmodics, or increased fluid intake may help alleviate postprocedural discomfort.

[0106] Endoscopic intratumoral drug delivery for bladder cancer provides a targeted, minimally invasive alternative for localized chemotherapy, immunotherapy, or novel drug treatments. By using precise needle guidance, controlled injection rates, and advanced cystoscopic imaging, this technique enhances drug retention within the tumor, reducing systemic exposure while improving therapeutic efficacy. Proper pressure monitoring, needle placement, and leakage prevention are crucial to ensure a successful and safe procedure.EXAMPLE 12 - Technical Specifications for Endoscopic Intratumoral Drug Delivery in Cervical Cancer.

[0107] Intratumoral drug delivery via endoscopic-guided injection is a minimally invasive approach for administering therapeutic agents directly into cervical cancer tumors. This techniqueimproves local drug concentration, reduces systemic side effects, and enhances treatment efficacy. A thin catheter with a needle is introduced through an endoscope (colposcope or hysteroscope) to precisely inject the drug into the tumor tissue. Below are the technical specifications for performing this procedure.1. Endoscopic System (Colposcope or Hysteroscope Specifications)i. Endoscope Type:a. Colposcope (for external cervical tumors) with high-resolution magnification. b. Hysteroscope (for tumors extending into the endocervical canal or uterus) for deeper access.ii. Optical Magnification:a. 5x-40x for high-definition visualization of cervical lesions.iii. Imaging Modalities:a. White-light colposcopy (WLC) for baseline visualization.b. Narrow-band imaging (NBI) or fluorescence-guided endoscopy to enhance tumor contrast.c. Ultrasound-guided (transvaginal or endoscopic) imaging for deep or submucosal tumors.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm to ensure smooth passage through the working channel.b. Length: 30-50 cm, depending on tumor location.c. Material: Biocompatible polymer (PTFE or silicone) for flexibility.ii. Needle Tip:a. Gauge: 22G-27G for controlled penetration with minimal tissue trauma.b. Length: 3-8 mm, based on tumor depth.c. Bevel Design: Short, angled bevel for precise intratumoral deposition.iii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate: Adjustable between 0.05-0.5 mL per minute to prevent leakage or mechanical rupture.3. Procedural Stepsi. Patient Preparation:a. Lithotomy position for optimal cervical access.b. Local anesthesia (cervical block) or mild sedation for patient comfort.ii. Tumor Localization:a. Colposcopic examination with acetic acid or Lugol’s iodine to enhance tumor visibility.b. Ultrasound-guided imaging (transvaginal or endoscopic) to assess tumor depth and size.iii. Catheter Insertion:a. The thin catheter with a needle tip is introduced through the working channel of the endoscope and advanced toward the tumor.iv. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring intratumoral penetration without perforating surrounding tissues.v. Drug Injection:a. The therapeutic agent is delivered at a controlled flow rate (0.05-0.5 mL per minute) to enhance absorption and prevent leakage.vi. Needle Withdrawal:a. The needle is slowly retracted, and the injection site is observed for bleeding or drug reflux.vii. Final Inspection:a. The cervix is re-examined using the colposcope or hysteroscope to confirm proper drug delivery.4. Safety Considerationsi. Pressure Monitoring:a. Ensures the tumor remains intact, avoiding excessive pressure that could cause tissue rupture.ii. Leakage Prevention:a. Slow injection rates and precise needle placement minimize drug diffusion into adjacent vaginal or uterine tissues.iii. Bleeding Control:a. The cervix is highly vascularized, so cautery, hemostatic agents, or absorbable gelatin sponges should be available.iv. Complication Management:a. Preparedness for hemorrhage, cervical trauma, or infection, which may require immediate intervention.v. Imaging Confirmation:a. Ultrasound or contrast-enhanced imaging may be used post-injection to verify drug retention in the tumor.5. Post-Procedure Carei. Monitoring:a. Patients should be observed for pelvic pain, vaginal bleeding, or infection postprocedure.ii. Follow-Up Imaging:a. MRI, CT, or repeat colposcopy / hysteroscopy may be performed to assess drug distribution and tumor response.iii. Pain Management:a. NSAlDs or mild analgesics may help alleviate discomfort.

[0108] Endoscopic intratumoral drug delivery for cervical cancer provides a minimally invasive, targeted therapy that enhances local drug concentration while reducing systemic toxicity. By employing colposcopic or hysteroscopic guidance, precise needle placement, controlled injection rates, and leakage prevention, this technique improves treatment efficacy and patient safety.EXAMPLE 13 - Technical Specifications for Intratumoral Drug Delivery via Surgical Incision in Thyroid Cancer

[0109] Intratumoral drug delivery using a surgical incision is a direct and effective method for administering therapeutic agents into thyroid tumors. This approach allows for precise drug deposition, bypassing systemic circulation and enhancing localized treatment while minimizing adverse effects. A thin catheter with a needle at its end is introduced through the surgical opening to accurately target the tumor mass. Below are the technical specifications for performing this procedure.1. Surgical Access and Incisioni. Surgical Approach:a. Cervical incision (low anterior neck, Kocher incision) for direct access to the thyroid gland.b. Incision Length: 3-6 cm, depending on tumor size and location.c. Layer Dissection:i. Skin and subcutaneous tissue carefully divided.ii. Platysma muscle incised and retracted.iii. Strap muscles (sternohyoid, sternothyroid) separated or divided (if necessary) to expose the thyroid gland.ii. Retractor System:a. Use of self-retaining retractors to provide clear surgical exposure.iii. Hemostasis Control:a. Bipolar cautery, ultrasonic scalpels, or ligation clips to manage bleeding from thyroid and surrounding vasculature.2. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm for easy maneuverability.b. Length: 15-25 cm to allow controlled navigation within the surgical field. c. Material: Biocompatible polymer (PTFE or silicone) for flexibility and durability. ii. Needle Tip:a. Gauge: 22G-27G to minimize tissue trauma while allowing effective drug infiltration.b. Length: 4-10 mm, depending on tumor depth.c. Bevel Design: Short, angled bevel for accurate penetration and uniform drug distribution.iii. Injection System:a. Manual or syringe pump injection system for precise drug administration. b. Flow Rate: Adjustable between 0.05-0.5 mL per minute to prevent leakage and ensure controlled diffusion.3. Procedural Stepsi. Patient Preparation:a. General anesthesia to maintain complete immobilization and pain control. b. Neck positioning: Extended using a shoulder roll for better surgical exposure. ii. Tumor Localization:a. Intraoperative ultrasound (IOUS) or direct palpation to identify tumor margins and depth.iii. Catheter Insertion:a. A thin catheter with a needle tip is introduced into the thyroid tumor through the surgical field.iv. Needle Placement:a. The needle is inserted at multiple sites within the tumor for uniform drug distribution.b. Real-time ultrasound guidance may be used to confirm proper depth and positioning.v. Drug Injection:a. The therapeutic agent is administered at a controlled flow rate (0.05-0.5 mL per minute) to optimize retention and minimize tissue disruption.vi. Needle Withdrawal:a. The needle is slowly removed, and the injection site is monitored for bleeding or drug reflux.vii. Closure of Incision:a. Hemostasis ensured using bipolar cautery or absorbable hemostatic materials. b. Surgical layers closed sequentially using absorbable sutures for deep tissues and non-absorbable sutures or skin glue for the skin.4. Safety Considerationsi. Pressure Monitoring:a. Avoids excessive intratumoral pressure, which could cause capsular rupture or drug leakage.ii. Leakage Prevention:a. Slow injection rates, accurate needle placement, and careful withdrawal minimize drug escape into surrounding tissues.iii. Vital Structure Protection:a. The thyroid is highly vascularized, and close proximity to the recurrent laryngeal nerve, trachea, and carotid artery necessitates careful handling.b. Neuromonitoring may be used to prevent nerve injury.iv. Complication Management:a. Preparedness for hematoma, infection, or thyroid capsule rupture, which may require additional intervention.v. Intraoperative Imaging Confirmation:a. Ultrasound or fluorescence-guided techniques can verify drug deposition and prevent misplacement.5. Post-Procedure Carei. Monitoring:a. Patients should be observed for neck swelling, hoarseness, breathing difficulty, or infection post-procedure.ii. Follow-Up Imaging:a. MRI, CT, or repeat ultrasound may be performed to assess drug retention and tumor response.iii. Pain Management:a. NSAIDs or mild opioids may be prescribed for post-operative discomfort. iv. Wound Care:a. Regular monitoring of the incision site for signs of infection or dehiscence.

[0110] Intratumoral drug delivery for thyroid cancer via a surgical incision is a highly precise and effective technique that ensures targeted therapy while minimizing systemic toxicity. With real-time ultrasound guidance, controlled injection rates, and careful surgical handling, this approach optimizes drug absorption while preserving thyroid function and adjacent critical structures.EXAMPLE 14 - Technical Specifications for Intratumoral Drug Delivery in Oral Cancer Using a Thin Catheter with a Needle.

[0111] Intratumoral drug delivery for oral cancer using a thin catheter with a needle is a minimally invasive technique designed to enhance local drug concentration while reducing systemic side effects. Given the anatomical complexity of the oral cavity, including its high vascularization and proximity to critical structures such as the tongue, jaw, and salivary glands, precise needle placement and controlled drug infusion are essential for effective treatment. This approach ensures optimal drug penetration into the tumor while minimizing tissue disruption and drug leakage.1. Catheter and Needle Systemi. Catheter Specifications:a. Outer Diameter: 1.0-2.5 mm for flexible insertion in restricted oral spaces. b. Length: 10-20 cm, depending on the tumor location and accessibility. c. Material: Biocompatible PTFE or silicone to ensure flexibility, durability, and minimal irritation.d. Lumen Configuration: Single or dual-lumen for drug infusion and potential aspiration of fluids.n. Needle Tip:a. Gauge: 22G-30G for minimized trauma in delicate oral tissues.b. Length: 5-12 mm, depending on the tumor's depth and proximity to critical structures.c. Bevel Design: Short, angled or blunt tip to prevent deep tissue penetration while ensuring intratumoral diffusion.iii. Injection System:a. Manual or automated syringe pump for precise drug delivery.b. Flow Rate: 0.05-0.5 mb per minute, adjusted based on tumor size and tissue permeability.2. Imaging and Guidance for Needle Placementi. Ultrasound-Guided Injection (Preferred for Soft Tissue Tumors):a. Provides real-time visualization of the tumor and surrounding structures.b. Helps in avoiding major blood vessels, nerves, and salivary ducts.ii. Endoscopic-Assisted Injection (For Hard-to-Reach Tumors):a. Used in posterior oral cavity tumors (e.g., base of tongue, oropharynx).b. Provides enhanced visualization when working in confined spaces.iii. CT or MRI Guidance (For Deep or Hard Tissue Tumors):a. Useful for tumors in bony structures such as the mandible or maxilla.b. Allows pre-procedural planning of injection sites to ensure even drug distribution.3. Procedural Stepsi. Patient Preparation:a. Local anesthesia (lidocaine or bupivacaine) or conscious sedation to manage discomfort.b. Patient positioned based on tumor location (e.g., supine with head slightly tilted for lateral tongue tumors).ii. Tumor Localization and Needle Insertion:a. Ultrasound or endoscopic visualization to confirm tumor margins.b. The catheter and needle are introduced percutaneously or intraorally, depending on tumor location.c. The needle is advanced into the tumor core to ensure optimal drug retention. iii. Drug Injection:a. Administered at a controlled flow rate (0.05-0.5 mL per minute) to prevent extravasation or reflux.b. Multi-point injection strategy used for large or irregularly shaped tumors to enhance coverage.iv. Needle Withdrawal and Post-Injection Monitoring:a. The needle is slowly withdrawn while applying slight pressure to prevent leakage. b. The injection site is observed for swelling, bleeding, or unexpected diffusion of the drug.4. Safety Considerationsi. Avoiding Drug Leakage and Swelling:a. Slow, controlled injection rates and proper tumor infiltration techniques prevent drug escape into normal tissues.ii. Avoiding Major Blood Vessels and Nerves:a. Ultrasound or endoscopic visualization ensures precise placement away from critical neurovascular structures.iii. Preventing Oral Tissue Damage and Ulceration:a. The use of fine-gauge needles (22G-30G) and atraumatic bevel tips minimizes mucosal injury.iv. Complication Management:a. Preparedness for hematoma, infection, or local necrosis, especially in vascularized oral structures.5. Post-Procedure Carei. Observation:a. Monitor for swelling, airway obstruction, or local tissue irritation.ii. Follow-Up Imaging:a. Ultrasound, CT, or MRI scans may be conducted post-injection to confirm drug distribution and tumor response.iii. Pain Management:a. NSAIDs or mild analgesics to alleviate discomfort.iv. Wound and Oral Hygiene Care:a. Patients should maintain good oral hygiene to reduce infection risk at the injection site.

[0112] Intratumoral drug delivery in oral cancer using a thin catheter with a needle is a minimally invasive yet highly effective approach for localized treatment. The use of ultrasound, endoscopic, or CT guidance, combined with fine-gauge needles and controlled injection rates, ensures precise drug administration while minimizing complications. This technique is particularly valuable in treating highly vascular and functionally sensitive areas within the oral cavity, enhancing therapeutic outcomes while preserving oral function and patient comfort.EXAMPLE 15 - Technical Specifications for Using a Syringe to Deliver a Drug Tntratumorally in Oral Cancer

[0113] Intratumoral drug injection using a syringe in oral cancer is a direct, minimally invasive technique that enhances localized drug delivery, maximizing therapeutic concentration while minimizing systemic toxicity. The precision of this method depends on selecting the appropriate syringe, needle size, and injection technique, considering the anatomical complexity of the oral cavity and the vascularized nature of oral tumors. Below are the technical specifications for performing this procedure safely and effectively.1. Syringe and Needle Systemi. Syringe Specifications:a. Capacity: 1 mL - 10 mL, depending on tumor size and drug volume requirements. b. Material: Sterile, disposable plastic or glass syringes for enhanced precision. c. Plunger Control: Smooth movement to allow controlled drug infusion without excessive force.ii. Needle Specifications:a. Gauge: 22G-30G for minimal trauma in delicate oral tissues.b. Length: 5-15 mm, depending on tumor depth and accessibility.c. Tip Design: Short bevel or blunt-tip to prevent deep penetration and tissue rupture. iii. Injection Volume:a. Small tumors (<1 cm): 0.1-0.5 mLper site.b. Medium tumors (1-3 cm): 0.5-2.0 mL per site.c. Large tumors (>3 cm): Multi-site injections with total volume up to 5-10 mL. iv. Injection Speed:a. Flow rate: 0.05-0.5 mL per minute to avoid drug leakage and tissue rupture.2. Imaging and Guidance for Needle Placementi. Ultrasound-Guided Injection (Preferred for Soft Tissue Tumors):a. Provides real-time visualization of the tumor and surrounding structures.b. Helps avoid major blood vessels, nerves, and salivary glands.ii. Manual Palpation and Visual Assessment (For Superficial Tumors):a. Used for clinically visible oral tumors (e.g., on the tongue, buccal mucosa, floor of the mouth).b. Ensures direct needle insertion at the tumor center for maximum drug retention.3. Procedural Stepsi. Patient Preparation:a. Local anesthesia (lidocaine, bupivacaine) for pain control at the injection site. b. Patient positioned upright or slightly reclined, depending on tumor location. ii. Tumor Localization and Needle Insertion:a. Ultrasound or direct visualization to confirm tumor margins.b. Needle is inserted at a shallow angle (10°-30°) to avoid excessive depth.iii. Drug Injection:a. Slow, controlled injection (0.05-0.5 mL per minute) to prevent tissue rupture. b. Multi-point injections may be needed for large or irregularly shaped tumors. iv. Needle Withdrawal and Post-Injection Monitoring:a. The needle is slowly retracted while applying slight pressure to prevent leakage. b. The injection site is observed for swelling, bleeding, or unexpected drug diffusion.4. Safety Considerationsi. Avoiding Drug Leakage and Swelling:a. Slow injection rates and proper needle depth prevent drug escape into normal tissues.ii. Avoiding Major Blood Vessels and Nerves:a. Ultrasound guidance ensures precise placement away from neurovascular structures.iii. Preventing Oral Tissue Damage and Ulceration:a. The use of fine-gauge needles (22G-30G) and atraumatic bevel tips minimizes mucosal injury.iv. Complication Management:a. Preparedness for hematoma, infection, or local necrosis, especially in vascularized oral structures.5. Post-Procedure Carei. Observation:a. Monitor for swelling, airway obstruction, or local tissue irritation.ii. Follow-Up Imaging:a. Ultrasound, CT, or MRI scans may be conducted post-injection to confirm drug distribution and tumor response.iii. Pain Management:a. NSAlDs or mild analgesics to alleviate discomfort.iv. Wound and Oral Hygiene Care:a. Patients should maintain good oral hygiene to reduce infection risk at the injection site.

[0114] Using a syringe for intratumoral drug delivery in oral cancer is an effective, precise, and minimally invasive method that allows for localized treatment while preserving surrounding healthy tissues. Slow, controlled injections, fine-gauge needles, and imaging guidance help optimize drug distribution while minimizing complications.EXAMPLE 16 - Technical Specifications for Using a Syringe to Deliver a Drug Intratumorally in Melanoma

[0115] Intratumoral injection using a syringe is an effective, minimally invasive technique for delivering therapeutic agents directly into melanoma tumors. This approach maximizes drug concentration in the tumor while reducing systemic exposure and associated side effects. Given the variability in melanoma size, depth, and location, precise syringe selection, needle gauge, and injection technique are crucial for optimal drug diffusion and tumor response.1. Syringe and Needle Systemi. Syringe Specifications:a. Capacity: 1 mL - 5 mL, depending on tumor size and required drug volume. b. Material: Sterile, disposable plastic or glass syringes for precision.c. Plunger Control: Smooth and calibrated to ensure controlled drug administration. ii. Needle Specifications:a. Gauge: 25G-30G (fine gauge for superficial melanomas) or 22G-25G (for deeper lesions).b. Length: 5-20 mm, depending on tumor thickness and penetration depth required. c. Tip Design: Short bevel or blunt-tip for precise drug deposition within the tumor. iii. Injection Volume:a. Small tumors (<1 cm): 0.1-0.5 mL per site.b. Medium tumors (1-3 cm): 0.5-2.0 mL per site.c. Large tumors (>3 cm): Multi-site injections with a total volume up to 5 mL. iv. Injection Speed:a. Flow rate: 0.05-0.5 mL per minute to avoid tissue rupture and leakage.2. Imaging and Guidance for Needle Placementi. Dermoscopic-Guided Injection (For Superficial Melanomas):a. Enhances visualization of tumor margins and vascularization.ii. Ultrasound-Guided Injection (For Deeper Melanomas):a. Provides real-time imaging for precise needle placement.b. Helps avoid blood vessels, underlying muscle, and connective tissues.3. Procedural Stepsi. Patient Preparation:a. Local anesthesia (lidocaine without epinephrine) to minimize pain at the injection site.b. Patient positioned to ensure stable and direct access to the melanoma lesion. ii. Tumor Localization and Needle Insertion:a. Dermoscopic or ultrasound visualization to define tumor boundaries.b. Needle inserted at a shallow angle (10°-30°) for superficial lesions or at 45° for deeper lesions.iii. Drug Injection:a. Slow, controlled injection (0.05-0.5 mb per minute) to enhance drug absorption and retention.b. Multi-site injections may be needed for irregularly shaped or large tumors. iv. Needle Withdrawal and Post-Injection Monitoring:a. The needle is slowly withdrawn while applying gentle pressure to prevent leakage. b. Injection site is monitored for redness, swelling, or unexpected diffusion.4. Safety Considerationsi. Avoiding Drug Leakage and Skin Necrosis:a. Slow injection and precise needle depth ensure drug containment within the tumor. ii. Avoiding Vascular Structures and Overlying Healthy Tissue:a. Ultrasound guidance minimizes the risk of vascular injury or systemic drug absorption.iii. Preventing Localized Skin Damage and Ulceration:a. Fine-gauge needles and careful injection speed control prevent tissue necrosis. iv. Complication Management:a. Preparedness for localized pain, swelling, or mild hemorrhage, particularly in highly vascularized areas.5. Post-Procedure Carei. Observation:a. Monitor for swelling, erythema, or necrotic changes at the injection site. ii. Follow-Up Imaging:a. Dermoscopy, ultrasound, or MRI to evaluate drug distribution and tumor response. iii. Pain Management:a. NSAIDs or mild analgesics to alleviate discomfort.iv. Wound Care:a. Patients should maintain clean and dry injection sites to minimize infection risk.

[0116] Intratumoral drug delivery using a syringe for melanoma treatment is a targeted, effective approach that allows localized treatment while minimizing systemic side effects. Slow, controlled injections, fine-gauge needles, and imaging guidance optimize drug distribution and tumor response, making it an important tool in melanoma therapy.EXAMPLE 17 - Technical Specifications for Using Stereotactically Placed Microcatheters to Deliver a Drug Tntratumorally in Brain Tumors

[0117] The use of stereotactically placed microcatheters for intratumoral drug delivery in brain tumors is a precise and minimally invasive technique that enables targeted therapeutic agent administration while minimizing systemic toxicity. This approach is particularly useful for treating glioblastomas, astrocytomas, and metastatic brain tumors, where systemic therapies have limited efficacy due to the blood-brain barrier (BBB). Stereotactic guidance ensures accurate catheter placement, optimizing drug diffusion within the tumor and reducing off-target effects.1. Stereotactic System and Microcatheter Specificationsa. Stereotactic Guidance Systemii. System Type: Frameless or frame-based stereotactic navigation (e.g., Leksell, Brainlab, or ROSA robotic systems).iii. Imaging Modalities: Preoperative MRI, CT, or intraoperative neuronavigation to map tumor boundaries.iv. Targeting Accuracy: Submillimeter precision (<1 mm error margin) to ensure optimal drug delivery.a. Microcatheter Specificationsv. Catheter Type:a. Single-lumen or multi-lumen flexible microcatheter for controlled drug infusion. b. Material: Biocompatible silicone or polyurethane to prevent tissue reaction. c. Outer Diameter: 0.4-1.2 mm (to minimize trauma to brain tissue).d. Length: Customized based on tumor depth and surgical trajectory.vi. Needle / Cannula Type for Placement:a. Gauge: 22G-26G for minimally invasive puncture.b. Tip Design: Beveled or blunt-tip to prevent excessive penetration beyond the target zone.vii. Infusion Port & Connector:a. Luer-lock or MRT-compatible infusion ports for precise drug administration control.2. Drug Infusion Parameters for Intratumoral Deliveryi. Injection Volume:a. Small tumors (<1 cm): 0.2-1 mL total volume.b. Medium tumors (1-3 cm): 1-5 mL total volume.c. Large tumors (>3 cm): Multiple microcatheters may be used for optimal coverage. ii. Flow Rate:a. 0.1-10 pL per minute (ultra-slow infusion to maximize drug retention).b. Convection-enhanced delivery (CED) may be used for higher volumes (10-50 pL / min).iii. Infusion Duration:a. Hours to days, depending on drug pharmacokinetics and tumor characteristics.3. Procedural Stepsi. Preoperative Planning & Imaging:a. MRI and / or CT-based stereotactic planning to map tumor boundaries, vasculature, and critical structures.ii. Patient Positioning & Fixation:a. If using a frame-based system, secure the patient’s head in a stereotactic frame. b. For frameless systems, attach fiducial markers or use intraoperative neuronavigation.iii. Catheter Placement:a. A small burr hole craniotomy (1-3 mm diameter) is performed.b. Microcatheter is stereotactically inserted through a guide cannula to the precise tumor location.iv. Drug Infusion:a. Infusion starts at ultra-low flow rates (0.1—10 pL / min) to allow uniform drug dispersion.b. Real-time monitoring (MRI, PET, or intraoperative imaging) can be used to assess drug distribution.v. Catheter Removal & Post-Procedure Monitoring:a. Catheter is gradually withdrawn to prevent rebound leakage.b. Patient is monitored for intracranial pressure changes, hemorrhage, or neurological deficits.4. Safety Considerationsi. Avoiding Backflow & Leakage:a. Slow infusion rates prevent drug reflux along the catheter tract.b. Using multi-port catheters can improve drug dispersion within the tumor.ii. Minimizing Brain Tissue Damage:a. Thin, flexible catheters reduce mechanical trauma.b. Optimized insertion trajectory ensures minimal disruption to eloquent brain regions.iii. Preventing Hemorrhage & Infection:a. Pre-procedure coagulation profile assessment is required.b. Sterile technique and prophylactic antibiotics may be used.iv. Monitoring Drug Distribution & Tumor Response:a. MRI with contrast or PET imaging can track real-time drug dispersion.b. Neurocognitive assessments are performed to detect any therapy-related side effects.5. Post-Procedure Carei. Neurological Monitoring:a. Close observation for seizures, focal deficits, or cerebral edema.ii. Follow-Up Imaging:a. MRI or PET scans at scheduled intervals to assess tumor response.iii. Pain & Symptom Management:a. Steroids or osmotic agents (e.g., mannitol) may be administered if there is concern for brain swelling.

[0118] Stereotactically placed microcatheters enable high-precision intratumoral drug delivery in brain tumors, overcoming the limitations of systemic therapies and the blood-brain barrier. By optimizing catheter placement, infusion rates, and drug dispersion, this technique enhances therapeutic efficacy while minimizing risks of brain injury, leakage, and neurotoxicity. This approach is particularly beneficial for glioblastomas, diffuse gliomas, and unresectable brain tumors, offering a targeted, minimally invasive treatment option.EXAMPLE 18 - Technical Specifications for Using Stereotactically Placed Microcatheters to Deliver a High-Concentration Drug Solution Intratumorally in Brain Tumors

[0119] The use of stereotactically placed microcatheters for intratumoral drug delivery in brain tumors provides a precise, localized treatment approach while minimizing systemic toxicity. To reduce intracranial pressure (ICP) increases, a high-concentration drug solution is used, allowing a lower total injection volume while ensuring effective drug retention within the tumor. This approach is particularly suitable for treating glioblastomas (GBM), diffuse astrocytomas, and metastatic brain tumors, where systemic therapy is often limited by the blood-brain barrier (BBB).1. Key Technical Considerationsi. High-Concentration Drug Solutiona. The drug formulation is optimized for low-volume, high-efficacy delivery. b. Drug selection considers high intratumoral retention properties, such as:i. Lipophilic or nanoparticle-based formulations to reduce diffusion into normal tissue.ii. Hydrogel or polymer-based sustained-release formulations to limit systemic washout.iii. Charged molecules or conjugated agents that bind to tumor extracellular matrix components.ii. Minimizing Total Injection Volumea. The inj ection volume is reduced to avoid sudden intracranial pressure increases that could lead to brain herniation, hemorrhage, or edema.b. Volumes typically range between:i. Small tumors (<1 cm): 50-200 pLii. Medium tumors (1-3 cm): 200-800 pLiii. Large tumors (>3 cm): Multi -catheter placement with staggered infusions may be required.iii. Stereotactic Guidance for Precision Deliverya. Imaging-based planning (MRI, CT, PET) to map tumor volume, vascularity, and eloquent structures.b. Frame-based or frameless robotic-assisted placement (e.g., Leksell, ROSA, Brainlab) ensures submillimeter precision (<1 mm error margin).2. Microcatheter & Infusion System Specificationsa. Microcatheter Designii. Outer Diameter: 0.3-1.0 mm (for minimal trauma).iii. Material: Biocompatible, flexible silicone or polyurethane to prevent inflammatory response.iv. Lumen Configuration: Single-lumen or multi-port design to enhance radial drug distribution.v. Tip Type:a. Beveled or stepped-tip to control directional flow.b. Porous-tip catheters (e.g., convection-enhanced delivery, CED) for uniform dispersion.c. Needle / Cannula Placementvi. Gauge: 22G-26G for controlled puncture and catheter guidance.vii. Entry Point: Stereotactically defined via burr hole craniotomy (1-3 mm diameter).a. Infusion Systemviii. Pump Type: Micro-infusion pump (e.g., Harvard Apparatus, Medtronic) for ultra-slow, controlled infusion.ix. Pressure Control:a. Low-pressure infusion (<30 mmHg) to prevent reflux and backflow.b. Stepwise ramp-up infusion to allow gradual tissue adaptation.x. Port Configuration: MRI-compatible Luer-lock or subcutaneous ports for staged administration.3. Drug Infusion Parametersi. Flow Rate:a. Ultra-slow infusion (0.1-5 pL / min) to prevent tissue disruption or fluid-induced swelling.b. CED protocol (10-50 pL / min for multi-port catheters) may be used for more effective drug penetration.ii. Infusion Duration:a. Typically 6-48 hours to ensure deep penetration without abrupt pressure spikes. b. Slow withdrawal technique prevents drug leakage along the catheter tract.iii. Post-Tnfusion Retention Strategy:a. Crosslinking hydrogel-based drugs for sustained release.b. Tumor matrix-binding agents to limit systemic diffusion.4. Procedural Workflowi. Preoperative Planning:a. MRI / CT fusion imaging to define tumor margins and critical structures. b. Selection of stereotactic entry trajectory to minimize vascular disruption. ii. Catheter Placement & Fixation:a. 1-3 mm burr hole craniotomy is performed under sterile conditions.b. Catheter inserted under stereotactic navigation to reach deep tumor zones. c. Catheter fixation with fibrin glue or suture anchoring to prevent displacement. iii. Drug Infusion Process:a. Gradual infusion initiation (starting at 0.1 pL / min) to avoid tissue swelling. b. Real-time imaging (MRI or PET-tracking) for drug distribution monitoring. iv. Post-Infusion Management:a. Catheter withdrawal over 24 hours to prevent fluid backflow.b. Edema control measures (e g., dexamethasone, mannitol).c. Neurological monitoring for ICP elevation, seizures, or focal deficits.5. Safety Considerationsi. Avoiding Tumor Rupture & Hemorrhage:a. Low-volume injection strategy to prevent tissue shear stress.b. Preoperative vascular imaging to avoid major blood vessels.ii. Preventing Drug Reflux & Leakage:a. Stepwise pressure control to prevent drug reflux along the catheter tract.b. Multi-port catheters for improved radial drug dispersion.iii. Minimizing Intracranial Pressure Spikes:a. Use of hyperosmotic agents (e.g., mannitol, hypertonic saline) pre-infusion. b. Continuous ICP monitoring in high-risk patients.iv. Post-Infusion Monitoring:a. MRI or PET imaging for drug retention analysis.b. Cognitive and motor assessments to track functional outcomes.

[0120] The use of high-concentration drug solutions via stereotactically placed microcatheters allows for precise intratumoral therapy in brain tumors while minimizing total injection volume and intracranial pressure elevations. By optimizing drug retention, infusion rate, and catheter design, this approach maximizes tumor exposure while reducing risks of brain edema, hemorrhage, and neurotoxicity. This technique is particularly beneficial for treating glioblastomas and deep-seated brain tumors where systemic therapies are ineffective due to the BBB.EXAMPLE 19 - Technical Specifications for a Robotic Drug-Releasing Device for Intratumoral Drug Delivery

[0121] The use of a robotic drug -releasing device for intratumoral drug delivery enables precise, controlled, and minimally invasive administration of therapeutic agents directly into solid tumors. This approach enhances drug retention, reduces systemic toxicity, and improves spatial drug distribution within the tumor mass. The robotic system integrates real-time imaging, automated needle guidance, and programmable drug infusion mechanisms, making it suitable for treating deep-seated, irregularly shaped, or highly vascularized tumors.1. Device Design & Components1.1 Robotic System Frameworki. Actuation Mechanism:a. Motorized or piezoelectric actuators for fine-tuned movement.b. Multi -degree-of-freedom (DOF) robotic arms for precise positioning.c. Miniaturized robotic mechanisms for laparoscopic, endoscopic, or percutaneous access.ii. Needle or Microcatheter System:a. Diameter: 18G-27G based on tumor size and location.b. Material: Flexible biocompatible polymers (e.g., polyimide) or metallic microtubes for structural integrity.c. Tip Design:i. Beveled or blunt-ended for controlled puncture.ii. Side-ported multi-hole designs for uniform intratumoral drug dispersion. d. Depth Control: Robotic depth sensors with real-time tissue resistance feedback to prevent excessive penetration.iii. Drug Reservoir & Delivery Mechanism:a. Reservoir Capacity: 0.5-10 mL, depending on tumor volume and drug concentration.b. Pump Type:i. Peristaltic or microfluidic-based pumps for controlled infusion.ii. Programmable drug release profiles (single or multi-phase).c. Flow Rate: Adjustable from 0.1 pL / min to 0.5 mL / min to prevent backflow and excessive pressure buildup.2. Integration with Imaging & Navigationi. Preoperative Planning:a. MRI, CT, or PET-based tumor mapping for volume, shape, and vascularity assessment.b. AT-based trajectory planning for safe robotic needle path optimization.ii. Real-Time Imaging Assistance:a. Ultrasound-guided navigation for soft-tissue tumors (liver, pancreas, breast).b. CT / MRI fluoroscopy integration for deep-seated tumors (brain, lung, prostate).c. Augmented reality (AR) overlay for enhanced surgeon visualization.iii. Precision Feedback Sensors:a. Tactile force sensors to detect needle-tissue interaction.b. Pressure-monitoring system to ensure infusion safety.fusion & Retention Optimizationi. Flow Rate Regulation:a. Slow infusion (0.1-10 pL / min) to prevent tissue rupture. b. Convection-enhanced delivery (CED) for deep drug penetration. ii. Leakage Prevention Mechanisms:a. Multi-needle simultaneous injection for radial drug spread. b. Hydrogel -based drug carriers for sustained release and retention. c. Electroporation-assisted delivery to enhance cellular uptake. iii. Customizable Drug Release Profiles:a. Single-bolus injection for rapid effect.b. Multi-phase release (continuous or pulsed) for prolonged drug action.c. On-demand remote-controlled drug delivery via wireless interface.Deployment Methodsi. Percutaneous Approach (CT / US-Guided):a. Used for liver, pancreatic, kidney, and soft tissue tumors. b. Fine robotic needle insertion through a small skin puncture. ii. Endoscopic-Assisted Approach:a. Used for esophageal, stomach, colorectal, and bladder tumors. b. Flexible robotic catheter inserted through natural orifices. iii. Stereotactic Approach (Brain Tumors):a. Submillimeter precision robotic guidance for deep brain tumors. b. MRI-compatible microcatheter system to minimize collateral damage.iv. Laparoscopic Approach:a. Used for peritoneal tumors, ovarian cancer, or deep-seated abdominal masses.b. Robotic-assisted trocars allow needle deployment with real-time imaging.Control Featuresi. Automated Pressure Monitoring:a. Prevents tumor rupture or backflow by adjusting infusion rates dynamically.b. Alarm system triggers if pressure exceeds safe thresholds. ii. Remote-Control & Al Integration:a. Machine learning models optimize drug dispersion based on realtime tissue response.b. Wireless control interface for remote adjustments in infusion parameters.iii. Post-Injection Monitoring:a. MRI / PET imaging for drug retention verification.b. Biomarker feedback system for real-time treatment efficacy tracking.

[0122] A robotic drug-releasing device for intratumoral injection provides high-precision, controlled drug administration in solid tumors while minimizing tissue damage and systemic exposure. Through real-time imaging, smart infusion control, and Al-assisted navigation, robotic systems optimize drug delivery efficiency and reduce procedural risks, making them ideal for brain, pancreatic, liver, and deep-seated tumors.EXAMPLE 20 - Technical Specifications for a Drug-Releasing Device with NearInfrared Light Port for Phototherapy in Tumors

[0123] The integration of a drug-releasing device with the capability to deliver near-infrared (NIR) light for phototherapy activation offers a promising therapeutic strategy for intratumoral drug delivery combined with localized activation via photodynamic, photothermal, photomechanical, photoimmunotherapy, activated photochemotherapy, or a combination thereof. This technology is suitable for various cancer types, including solid tumors in organs such as the liver, pancreas, breast, and prostate. The device is designed to administer precisely dosed drugs into the tumor while using NIR light to activate phototherapy agents for targeted therapeutic effects, enhancing drug efficacy and minimizing damage to surrounding healthy tissues.1. Device Design & Components1.1 Drug-Releasing Device Frameworki. Laparoscope, Endoscope, or Robotic Drug-Releasing Device:a. Laparoscopic or endoscopic access for abdominal, gastrointestinal, or pelvic tumors (e.g., colorectal, ovarian, or liver cancer).b. Robotic-assisted drug delivery for deep-seated tumors, enabling precise targeting of hard-to-reach tumors such as pancreatic or brain tumors.c. Device diameter: Typically 3-10 mm for minimally invasive procedures.d. Material: Biocompatible silicone, polyurethane, or stainless steel for structural flexibility, durability, and ease of sterilization. elivery Mechanismi. Catheter or Microcatheter System:a. Flexible catheters designed for intratumoral placement, allowing for multi-port delivery of the drug.b. Needle design: Side-hole or micro-needle tip for controlled infusion and even distribution of the drug within the tumor. c. Reservoir Capacity: Drug reservoir is typically 1-5 mL, depending on tumor size and drug concentration.d. Flow Rate Control: The system should allow for adjustable flow rates between 0.1 pL / min to 5 mL / min to accommodate various drugs, including biologies and small molecules.frared Light Activation Porti. Integrated NIR Light Source:a. Optical fibers or LED arrays embedded in the catheter or microcatheter, designed to deliver NIR light (600-950 nm) into the tumor. Or longer NIR wavelengths 1000-1800 nm to cover theNIR-II or NIR-III windows. Additionally, NIR wavelengths of 2100-2300 nm could be used.b. Light Delivery Port: Specialized laser or LED light sources integrated into the device for targeted activation of photosensitive drugs or photosensitizers.c. Laser Power Output: Adjustable from 50 mW to 500 mW, depending on the tumor size and required light exposure. d. Light Distribution: Light fibers should be capable of uniform radial distribution over the tumor, delivering penetration depths of up to 2-5 cm depending on tumor density and location. Mechanismsi. Robotic / Automated Control:a. A programmable infusion pump to administer the drug over time with precise control over flow rates.b. The NIR light delivery system is synchronized with the drug infusion, ensuring timed activation of the drug with maximum therapeutic benefit.c. Integration with a robotic arm or stereotactic navigation system to achieve optimal catheter placement and light activation for minimized off-target effects.peration & Workflowative Planningi. Imaging Modalities:a. Preoperative planning involves CT, MRI, or PET scans to map the tumor location, size, and vascularity.b. Use of biomarker-based imaging (e.g., MRT / PET tracers) to identify photosensitive drug uptake and optimize light delivery placement.ii. Stereotactic or Robotic Navigation:a. Stereotactic targeting or robotic-guided catheter placement ensures precise delivery to tumor regions.b. Multi-port injection sites may be used for large or irregular tumors, with the catheter providing radial distribution for optimal coverage.njection & Light Activationi. Drug Infusion Process:a. The device is inserted into the tumor via laparoscopic, endoscopic, or percutaneous approach.b. Intratumoral drug release is initiated, with the flow rate adjusted based on tumor volume, tissue type, and therapeutic agent. c. Gradual infusion (typically over 1-4 hours) allows for deep drug penetration without causing tumor rupture or excessive pressure buildup.ii . Light Activation :a. After drug infusion, NIR light is administered via optical fibers embedded in the catheter.b. NIR light exposure is controlled by timing, intensity, and duration settings, delivering phototherapy activation (e.g. molecular jackhammer) of the drug for enhanced cytotoxicity. c. Light Delivery: Continuous or pulsed mode depending on the nature of the phototherapy agent, with real-time monitoring of light exposure ensuring effective drug activation.eatment Monitoringi. Imaging:a. Real-time MRI, CT, or PET scans post-treatment to assess drug distribution, tumor response, and tissue damage.b. Fluorescence-guided imaging for visual confirmation of drug activation, ensuring proper NIR light coverage.ii. Follow-up Care:a. Tumor markers or biopsy for evaluating treatment success and monitoring for recurrence.b. Surveillance imaging to monitor long-term effects of therapy.Control Featuresting Over-infusion & Leakagei. Flow Rate Regulation:a. Automated pressure feedback sensors ensure that infusion rates are within safe limits to prevent tissue rupture.b. Adjustable catheter lumens or valves control drug flow, minimizing leakage into surrounding tissues.xposure Safetysity Regulation:a. The light intensity is controlled based on tumor size, photosensitizer concentration, and tissue depth to avoid collateral damage to healthy surrounding tissues.b. Safety cutoffs are implemented to prevent overexposure of sensitive tissues to the NIR light.3.3 Remote Monitoring & Controli. Wireless Interface:a. The device is equipped with a wireless monitoring system to adjust infusion and light activation in real-time based on tumor response and ongoing treatment feedback.b. Automatic reporting of treatment parameters ensures that clinicians can track progress and adjust treatment if necessary.

[0124] The integration of a drug-releasing device with near-infrared light delivery for photodynamic therapy provides a cutting-edge approach to treating solid tumors. This combination therapy enhances the effectiveness of intratumoral drug delivery while leveraging the unique capabilities of NIR light activation to target tumor cells selectively, reduce systemic toxicity, and improve clinical outcomes. With precise surgical navigation, programmable drug infusion, and synchronized phototherapy, this device offers a promising strategy for localized cancer treatment in a minimally invasive manner.EXAMPLE 21 - Technical Specifications for Intratumoral Drug Delivery in Thyroid Cancer Using Laparoscopy.

[0125] Intratumoral drug delivery in thyroid cancer using laparoscopy is a minimally invasive technique that enables precise, localized administration of therapeutic agents directly into thyroid tumors. This method enhances drug concentration within the tumorvic while minimizing systemic toxicity. The procedure involves using a laparoscope to guide a thin catheter with a needle tip to the tumor for targeted drug injection. Below are the technical specifications for this technique.1. Laparoscopic Systemiv. Laparoscope Specifications:a. Diameter: 5-10 mm for optimal maneuverability and visualization.b. Viewing Angle: 30° for enhanced visualization of the thyroid gland and surrounding structures.c. Resolution: HD or 4K for high-definition imaging of thyroid tumors, trachea, and vascular structures.v. Access Ports:a. Typically, 3 laparoscopic ports (5-10 mm) are used.b. One port is dedicated to the laparoscope, one for the catheter insertion, and another for auxiliary instruments if needed.vi. Insufflation System:a. Carbon dioxide (CO2) insufflation at 6-8 mmHg to create a small working space in the anterior neck region, preventing excessive tissue compression. vii. Neck Retraction and Positioning:a. A laparoscopic retractor or external neck positioning is used to stabilize the thyroid gland and optimize surgical access.b. The patient is placed in the supine position with slight neck extension to expose the thyroid area.. Catheter and Needle Systemix. Catheter Specifications:1. Outer Diameter: 1-2 mm for minimal invasiveness and flexibility in navigating the thyroid gland.2. Length: 15-25 cm to ensure adequate reach and precise placement in the tumor.3. Material: Biocompatible polymer (PTFE or silicone) to reduce tissue trauma. x. Needle Tip:1. Gauge: 20-25G for controlled tumor penetration while reducing bleeding risks.2. Length: 8-12 mm to ensure intratumoral delivery without penetrating beyond the gland.3. Bevel Design: Short, angled bevel for smooth insertion into the thyroid tumor. xi. Injection System:1. Syringe pump or manual injection system for controlled drug administration. 2. Flow rate adjustable between 0.05-0.5 mL per minute to optimize perfusion and minimize leakage.. Procedural Stepsv. Patient Positioning:o The patient is placed in the supine position with slight neck extension to optimize exposure of the thyroid gland.vi. Laparoscopic Access:o The primary laparoscope is inserted via a small incision below the chin or at the suprasternal notch.o Secondary ports are placed for catheter insertion and tissue manipulation. vii. Tumor Localization:o The thyroid tumor is identified using laparoscopic visualization, and intraoperative ultrasound (IOUS) may be used for precise localization.viii. Catheter Insertion:o A thin catheter with a needle tip is inserted through a dedicated port and guided towards the tumor under direct visualization.ix. Needle Placement:o The needle is carefully inserted into the tumor, ensuring controlled penetration without breaching the thyroid capsule.x. Drug Injection:o The drug is administered at a controlled rate of 0.05-0.5 mb per minute to ensure uniform distribution.o Slow injection prevents overpressurization and reduces the risk of leakage. xi. Needle Withdrawal:o The needle is slowly withdrawn, with minimal tissue disturbance to prevent drug escape.o Gentle manual compression over the injection site may be applied to reduce leakage.xii. Site Inspection:o The thyroid gland is inspected for signs of bleeding, leakage, or structural damage before closing the laparoscopic ports.. Safety Considerationsiv. Pressure Monitoring:o Monitoring intratumoral pressure prevents mechanical rupture of the tumor or drug backflow.v. Leakage Prevention:o Proper needle positioning and slow injection rates help minimize drug leakage into surrounding thyroid tissue.vi. Bleeding Control:o The high vascularity of the thyroid requires careful needle insertion to prevent hemorrhage.o Hemostatic agents may be applied in case of minor bleeding.vii. Complication Management:o Preparedness for complications such as capsular rupture, tracheal compression, or vocal cord nerve damage, which may require additional intervention. viii. Imaging Confirmation:o Intraoperative ultrasound (IOUS) or contrast-enhanced imaging may be used postinjection to confirm adequate drug distribution within the tumor.. Post-Procedure Carev. Monitoring:a. Patients should be monitored for signs of airway compromise, voice changes, or hematoma formation postoperatively.vi. Imaging Follow-Up:a. Ultrasound or CT scans may be performed to assess drug retention within the tumor and detect any complications.vii. Pain Management:a. Local anesthetics or systemic analgesia may be required to manage post- laparoscopic discomfort.

[0126] Laparoscopic intratumoral drug delivery in thyroid cancer is a precise, minimally invasive method for localized chemotherapy, immunotherapy, or experimental treatments. This technique allows targeted drug administration while reducing systemic exposure and surgical risks. Careful control of injection speed, needle placement, and pressure monitoring ensures safe and effective treatment.EXAMPLE 22 - Technical Specifications for Intratumoral Drug Delivery in Kidney Cancer Using Laparoscopy.

[0127] Laparoscopic intratumoral drug delivery in kidney cancer is a minimally invasive approach that allows for the direct administration of therapeutic agents into renal tumors. This method increases drug concentration within the tumor while reducing systemic toxicity and preserving surrounding healthy kidney tissue. The procedure involves using a laparoscope to guide a thin catheter with a needle tip for precise drug injection into the renal tumor. Below are the technical specifications for this technique.1. Laparoscopic Systemix. Laparoscope Specifications:a. Diameter: 5-12 mm for enhanced maneuverability and optimal visualization. b. Viewing Angle: 30° to provide a wide field of view of the kidney and surrounding structures.c. Resolution: HD or 4K for clear imaging of the renal tumor, vascular structures, and adjacent organs.x. Access Ports:a. Typically, 3-4 laparoscopic ports (5-12 mm) are used.b. One port is dedicated to the laparoscope, one for catheter insertion, and additional ports for auxiliary instruments if needed.xi. Insufflation System:a. Carbon dioxide (CO2) insufflation at 10-15 mmHg to create adequate working space and maintain visibility.xn. Kidney Stabilization:a. Laparoscopic graspers or retractors may be used to stabilize the kidney and expose the tumor for accurate catheter positioning.2. Catheter and Needle Systemvi. Catheter Specifications:a. Outer Diameter: 1-2 mm for minimal invasiveness and flexible navigation. b. Length: 25-35 cm to accommodate different tumor locations within the kidney. c. Material: Biocompatible polymer (PTFE or silicone) to ensure smooth insertion and durability.vii. Needle Tip:a. Gauge: 18-22G for precise tumor penetration while minimizing tissue trauma. b. Length: 10-20 mm to ensure intratumoral placement without breaching the renal capsule.c. Bevel Design: Short, angled bevel for controlled penetration into the solid renal mass.viii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate adjustable between 0.1-1.0 mL per minute to optimize drug distribution and prevent backflow.3. Procedural Stepsiv. Patient Positioning:a. The patient is placed in the lateral decubitus position for optimal access to the affected kidney.v. Laparoscopic Access:a. The primary laparoscope is inserted, followed by secondary ports for catheter insertion and instrument manipulation.vi. Tumor Localization:a. The renal tumor is identified using laparoscopic visualization and intraoperative ultrasound (IOUS) for precise localization.vii. Catheter Insertion:a. A thin catheter with a needle tip is introduced through a dedicated port and directed toward the tumor under real-time visualization.viii. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring proper depth without puncturing the renal capsule.ix. Drug Injection:a. The drug is administered at a controlled rate of 0.1-0.5 mL per minute to maximize perfusion while preventing excessive pressure buildup.x. Needle Withdrawal:a. The needle is slowly withdrawn, and gentle manual compression may be applied to minimize leakage.xi. Site Inspection:a. The renal tumor site is inspected for signs of bleeding, drug leakage, or structural compromise before completing the procedure.4. Safety Considerationsiii. Pressure Monitoring:a. Intratumoral pressure monitoring prevents mechanical rupture or drug backflow. iv. Leakage Prevention:a. Controlled needle positioning and slow injection rates reduce drug leakage into the renal parenchyma.v. Bleeding Control:a. Given the high vascularity of renal tumors, careful needle insertion is critical to avoid hemorrhage.b. Hemostatic agents may be applied if necessary.vi. Complication Management:a. Preparedness for complications such as capsular rupture, vascular injury, or urinary obstruction, which may require further intervention.vii. Imaging Confirmation:a. Intraoperative ultrasound (IOUS) or contrast-enhanced imaging may be used postinjection to confirm drug distribution within the tumor.5. Post-Procedure Careiv. Monitoring:a. Patients should be monitored for hematuria, flank pain, or signs of renal dysfunction postoperatively.v. Imaging Follow-Up:a. CT or MRI scans may be performed to assess intratumoral drug retention and detect any complications.vi. Pain Management:a. Local anesthetics or systemic analgesia may be administered for post- laparoscopic discomfort.

[0128] Laparoscopic intratumoral drug delivery in kidney cancer provides a precise, minimally invasive technique for localized chemotherapy, immunotherapy, or experimental treatments. This approach ensures targeted drug administration while reducing systemic toxicity and preserving kidney function. Proper control of injection speed, needle placement, and pressure monitoring ensures safe and effective treatment delivery.EXAMPLE 23 - Technical Specifications for Intratumoral Drug Delivery in Prostate Cancer Using Laparoscopy.

[0129] Laparoscopic intratumoral drug delivery in prostate cancer is a minimally invasive technique that allows for direct, localized administration of therapeutic agents into prostate tumors. This approach enhances drug concentration within the tumor while minimizing systemic sideeffects. The procedure utilizes a laparoscope to guide a thin catheter with a needle tip into the prostate for precise drug injection. Below are the technical specifications for this method.1. Laparoscopic Systemviii. Laparoscope Specifications:a. Diameter: 5-10 mm for maneuverability in the pelvic region.b. Viewing Angle: 30° for improved visualization of the prostate and surrounding structures.c. Resolution: HD or 4K for clear imaging of the prostate gland, neurovascular bundles, and adjacent organs.ix. Access Ports:a. Typically, 3-4 laparoscopic ports (5-12 mm) are used.b. One port for the laparoscope, one for the catheter insertion, and others for auxiliary instruments if needed.x. Insufflation System:a. Carbon dioxide (CO2) insufflation at 10—12 mmHg to create adequate working space in the pelvic cavity.xi. Prostate Stabilization:a. Laparoscopic retractors or graspers may be used to stabilize the prostate for accurate catheter positioning.2. Catheter and Needle Systemvi. Catheter Specifications:a. Outer Diameter: 1-2 mm for minimal invasiveness and flexible maneuvering. b. Length: 20-30 cm to ensure adequate reach within the pelvic cavity. c. Material: Biocompatible polymer (PTFE or silicone) to reduce tissue irritation. vii. Needle Tip:a. Gauge: 20-25G for controlled penetration while minimizing trauma to theprostate.b. Length: 8-15 mm to ensure intratumoral delivery without puncturing beyond the gland.c. Bevel Design: Short, angled bevel for smooth and controlled insertion. viii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate adjustable between 0.05-0.5 mL per minute to optimize distribution and prevent leakage.3. Procedural Stepsiv. Patient Positioning:a. The patient is placed in the Trendelenburg position to improve access to the prostate and pelvic region.v. Laparoscopic Access:a. The primary laparoscope is inserted through a small incision near the umbilicus. b. Secondary ports are placed for catheter insertion and instrument manipulation. vi. Tumor Localization:a. The prostate tumor is identified using laparoscopic visualization and intraoperative ultrasound (IOUS) for precise guidance.vii. Catheter Insertion:a. A thin catheter with a needle tip is inserted through a dedicated port and guided toward the tumor under direct visualization.viii. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring proper depth without breaching the prostatic capsule.ix. Drug Injection:a. The drug is administered at a controlled rate of 0.05-0.5 mL per minute to ensure uniform distribution.b. Slow injection minimizes pressure buildup and prevents leakage.x. Needle Withdrawal:a. The needle is slowly withdrawn, and gentle manual compression may be applied to minimize drug escape.xi. Site Inspection:a. The prostate gland is inspected for bleeding, leakage, or other complications before closing the laparoscopic ports.4. Safety Considerationsvi. Pressure Monitoring:a. Monitoring intratumoral pressure prevents mechanical rupture or drug reflux. vii. Leakage Prevention:a. Proper needle positioning and slow injection rates minimize drug diffusion into adjacent tissue.viii. Bleeding Control:a. Due to the high vascularity of the prostate, care must be taken to avoid vascular injury.b. Hemostatic agents may be applied if minor bleeding occurs.ix. Complication Management:a. Preparedness for complications such as capsular rupture, urethral compression, or nerve injury, which may require further intervention.x. Imaging Confirmation:a. Intraoperative ultrasound (IOUS) or contrast-enhanced imaging may be used postinjection to confirm intratumoral drug distribution.5. Post-Procedure Careiv. Monitoring:a. Patients should be monitored for urinary retention, hematuria, or pelvic pain postoperatively.v. Imaging Follow-Up:a. MRI or ultrasound may be performed to assess intratumoral drug retention and detect any complications.vi. Pain Management:a. Local anesthetics or systemic analgesia may be administered to manage post- laparoscopic discomfort.

[0130] Laparoscopic intratumoral drug delivery in prostate cancer offers a precise, minimally invasive approach for localized chemotherapy, immunotherapy, or experimental treatments. This technique ensures targeted drug administration, reducing systemic exposure while maintaining prostate function. Careful control of injection speed, needle placement, and pressure monitoring ensures safe and effective treatment delivery.EXAMPLE 24 - Technical Specifications for Intratumoral Drug Delivery in Throat Cancer Using Endoscopy.

[0131] Endoscopic intratumoral drug delivery is an advanced, minimally invasive technique designed to administer therapeutic agents directly into tumors located in the throat (larynx, hypopharynx, or oropharynx). This method ensures a high local drug concentration while reducing systemic toxicity. The procedure involves using a flexible or rigid endoscope to guide a thin catheter with a needle tip for precise intratumoral injection. The following are the technical specifications for this approach.1. Endoscopic Systemviii. Endoscope Type:a. Flexible laryngoscope or nasopharyngoscope for transnasal access to the larynx and hypopharynx.b. Rigid transoral endoscope for better stability and visualization in the oropharynx and supraglottic tumors.c. Outer Diameter: 3-6 mm (flexible) or 5-10 mm (rigid) to fit through the nasal passage or oral cavity.d. Working Channel Diameter: > 2.0 mm to accommodate catheter insertion.e. Working Length: 30-60 cm to reach different areas within the throat.f. Angulation: Up to 160° to maneuver around complex anatomical structures. ix. Imaging Modalities:a. White-light endoscopy (WLE) for primary visualization.b. Narrow-band imaging (NBI) or autofluorescence endoscopy (AFE) for enhanced tumor delineation.c. Endoscopic ultrasound (EUS) for deep tumor assessment and precise needle guidance.2. Catheter and Needle Systemvi. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm for smooth passage through the endoscope channel.b. Length: 50-100 cm to allow access to tumors in different throat regions. c. Material: Biocompatible polymer (PTFE or silicone) to minimize irritation and maximize flexibility.vii. Needle Tip:a. Gauge: 22-27G for precise penetration with minimal trauma.b. Length: 3-10 mm, depending on tumor depth.c. Bevel Design: Short, angled bevel for controlled intratumoral placement. viii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate: Adjustable between 0.05-0.5 mL per minute to optimize drug distribution and prevent tissue rupture.3. Procedural Stepsiv. Patient Preparation:a. Topical anesthesia (lidocaine spray) or mild sedation to reduce discomfort.b. Flexible or rigid endoscope insertion through the nose (transnasal approach) or mouth (transoral approach).v. Tumor Localization:a. WLE, NBI, or AFE is used to visualize and assess tumor margins.b. EUS guidance may assist in evaluating tumor depth and needle positioning. vi. Catheter Insertion:a. A thin catheter with a needle tip is inserted through the endoscope’s working channel toward the tumor.vii. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring accurate penetration into the malignant tissue while avoiding adjacent structures like blood vessels and cartilage.viii. Drug Injection:a. The therapeutic agent is injected at a controlled flow rate (0.05-0.5 mL per minute) to enhance tumor perfusion while minimizing drug leakage and tissue rupture.ix. Needle Withdrawal:a. The needle is slowly retracted, and the injection site is examined for drug reflux or bleeding.x. Final Inspection:a. The tumor area is re-evaluated with the endoscope to confirm proper drug deposition.4. Safety Considerationsiv. Pressure Monitoring:a. Ensures tissue integrity is maintained, preventing mechanical rupture or drug leakage.v. Leakage Prevention:a. Slow injection rates and precise needle positioning help keep the drug localized within the tumor.vi. Bleeding Control:a. The throat region is highly vascularized, so cautery, hemostatic agents, or absorbable gelatin sponges should be available.vii. Complication Management:a. Preparedness for laryngospasm, airway obstruction, or accidental mucosal perforation, which may require emergency intervention.viii. Imaging Confirmation:a. EUS or contrast-enhanced endoscopy may be used post-injection to confirm drug retention in the tumor.5. Post-Procedure Careiv. Monitoring:a. Patients should be observed for airway compromise, pain, or difficulty swallowing post -procedure.v. Follow-Up Imaging:a. MRI, CT, or repeat endoscopy may be performed to assess drug distribution and tumor response.vi. Pain Management:a. Topical anesthetics, systemic analgesia, or corticosteroids may be used for postprocedural discomfort.

[0132] Endoscopic intratumoral drug delivery for throat cancer provides a targeted, minimally invasive approach to chemotherapy, immunotherapy, or experimental treatments. This technique enhances local drug concentration while minimizing systemic toxicity. Proper injection control, needle placement, and pressure monitoring are crucial for effective treatment delivery in this delicate anatomical region.EXAMPLE 25 - Technical Specifications for Endoscopic Intratumoral Drug Delivery in Stomach Cancer.

[0133] Endoscopic-assisted intratumoral drug delivery is a minimally invasive technique for administering therapeutic agents directly into gastric tumors (stomach cancer). By using an endoscope to guide a thin catheter with a needle, the procedure allows precise targeting of tumors while minimizing systemic toxicity and improving local drug efficacy. Below are the technical specifications for performing this procedure.1. Endoscopic System (Gastroscope Specifications)v. Endoscope Type:a. Flexible gastroscope for transoral access to the stomach.b. Dual-channel endoscope (optional) to allow simultaneous visualization and catheter manipulation.vi. Outer Diameter:a. 9-12 mm for adult therapeutic gastroscopes.vii. Working Channel Diameter:a. > 2.8 mm to accommodate the catheter and needle system.viii. Working Length:a. 100-120 cm to reach all regions of the stomach.ix. Imaging Modalities:a. White-light endoscopy (WLE) for initial tumor visualization.b. Narrow-band imaging (NBI) or chromoendoscopy to enhance tumor contrast. c. Endoscopic ultrasound (EUS) for tumor depth assessment and precise needle guidance.2. Catheter and Needle Systemv. Catheter Specifications:a. Outer Diameter: 1.5-2.5 mm for smooth passage through the endoscope channel.b. Length: 150-180 cm for adequate reach into the stomach.c. Material: Biocompatible polymer (PTFE or silicone) for flexibility and durability.vi. Needle Tip:a. Gauge: 19G-25G for controlled intratumoral penetration.b. Length: 4-10 mm, depending on tumor depth.c. Bevel Design: Short, angled bevel for accurate delivery into tumor tissue. vii. Injection System:a. Syringe pump or manual injection system for controlled drug administration. b. Flow rate: Adjustable between 0.05-0.5 mb per minute to optimize drug absorption while preventing leakage or mechanical rupture.3. Procedural Stepsv. Patient Preparation:a. Fasting (6-8 hours prior) to ensure a clear gastric field.b. Local throat anesthesia (lidocaine spray) or mild sedation to improve patient comfort.vi. Tumor Localization:a. White-light endoscopy (WLE) or NBI to visualize the tumor.b. EUS guidance to assess tumor depth and needle positioning.vii. Catheter Insertion:a. A thin catheter with a needle tip is inserted through the working channel of the endoscope and advanced toward the tumor.viii. Needle Placement:a. The needle is carefully inserted into the tumor, ensuring precise penetration into the malignant tissue.ix. Drug Injection:a. The therapeutic agent is administered at a controlled flow rate (0.05-0.5 mL per minute) to enhance drug retention and prevent tissue rupture or leakage. x. Needle Withdrawal:a. The needle is slowly retracted, and the injection site is inspected for any signs of bleeding or drug reflux.XI. Final Inspection:a. The tumor area is re-examined using the endoscope to confirm proper drug deposition.4. Safety Considerationsv. Pressure Monitoring:a. Maintains tumor integrity, preventing excessive pressure that could lead to perforation or leakage.vi. Leakage Prevention:a. Slow injection rates and precise needle positioning minimize drug reflux into the stomach lumen.vii. Bleeding Control:a. The stomach is highly vascularized, so cautery, hemostatic agents, or absorbable gelatin sponges should be available.viii. Complication Management:a. Preparedness for gastric bleeding, mucosal damage, or perforation, which may require immediate intervention.ix. Imaging Confirmation:a. EUS or contrast-enhanced endoscopy may be used post-injection to verify drug retention in the tumor.5. Post-Procedure Careiii. Monitoring:a. Patients should be observed for abdominal pain, nausea, or bleeding postprocedure.iv. Follow-Up Imaging:a. MRI, CT, or repeat endoscopy may be performed to assess drug distribution and tumor response.v. Dietary Recommendations:a. Soft or liquid diet may be recommended for a short period post-procedure.

[0134] Endoscopic intratumoral drug delivery for stomach cancer is a minimally invasive, targeted therapy that enhances local drug concentration while reducing systemic toxicity. Utilizing advanced imaging techniques (EUS, NBI, or chromoendoscopy) ensures precise needle placement and effective drug absorption within the tumor. Proper flow rate control, needle positioning, and leakage prevention are crucial to optimizing treatment efficacy and patient safety.EXAMPLE 26 - Technical Specifications for Intratumoral Drug Delivery in Breast Cancer Using a Thin Catheter with a Needle.

[0135] Intratumoral drug delivery in breast cancer using a thin catheter with a needle allows for localized administration of therapeutic agents directly into the tumor. This minimally invasive technique enhances drug concentration at the tumor site, reduces systemic exposure, and improves treatment efficacy. The catheter system is designed for precise intratumoral placement under imaging guidance, ensuring optimal drug distribution within the tumor mass. Below are the technical specifications for performing this procedure.1. Catheter and Needle Systemv. Catheter Specifications:a. Outer Diameter: 1.5-3 mm for smooth percutaneous insertion.b. Length: 10-25 cm, depending on the depth and location of the tumor. c. Material: Biocompatible polymer (PTFE, silicone) to ensure flexibility and minimal tissue reaction.d. Lumen Configuration: Single or multi-lumen design for drug infusion and aspiration.vi. Needle Tip:a. Gauge: 22G-27G for fine penetration with minimal tissue trauma.b. Length: 5-15 mm, adaptable to tumor depth.c. Bevel Design: Short, angled bevel for controlled insertion and targeted drugdeposition.vii. Injection System:a. Manual or automated syringe pump to control the drug infusion rate. b. Flow Rate: 0.05-1.0 mL per minute, depending on tumor size and tissue permeability.2. Imaging Guidance for Needle Placementv. Ultrasound-Guided Placement (Preferred):a. High-resolution, real-time imaging allows accurate needle positioning. b. Doppler ultrasound can help avoid major blood vessels and reduce the risk of bleeding.vi. MRI or CT-Guided Placement (For Deeper Lesions):a. MRI guidance ensures precise needle depth and intratumoral drug distribution. b. CT-guided procedures can be used for tumors in challenging anatomical locations.3. Procedural Stepsv. Patient Preparation:a. Patient positioned in supine or slightly oblique position, depending on tumor location.b. Local anesthesia (lidocaine) for pain control at the insertion site.vi. Tumor Localization:a. Ultrasound or MRI confirmation of tumor margins and vascular structures. vii. Catheter and Needle Insertion:a. A thin catheter with a needle tip is percutaneously inserted into the tumor under imaging guidance.b. The needle tip is positioned within the tumor’s central and peripheral regions for even drug distribution.viii. Drug Injection:a. The therapeutic agent is administered at a controlled flow rate (0.05-1.0 mL per minute) to ensure uniform diffusion.b. Multi-point injection may be performed to enhance intratumoral penetration. ix. Needle Withdrawal and Catheter Removal:a. The needle is slowly retracted while ensuring no drug leakage.b. The insertion site is monitored for bleeding or swelling.x. Final Assessment:a. Ultrasound or MRI verification may be used post-injection to confirm drug retention and tumor coverage.4. Safety Considerationsviii. Leakage Prevention:a. Slow injection rates, proper needle positioning, and multi-point injections prevent extravasation.ix. Avoiding Hematoma Formation:a. Ultrasound guidance helps avoid major blood vessels, minimizing bleeding risk. x. Pain and Tissue Damage Reduction:a. Fine-gauge needles and flexible catheter systems ensure minimal fibrosis or necrosis.xi. Complication Management:a. Preparedness for bleeding, infection, or focal tissue irritation post -injection.5. Post-Procedure Careiv. Monitoring:a. Observation for 1-2 hours post-procedure to assess for swelling, hematoma, or leakage.v. Follow-Up Imaging:a. MRI, ultrasound, or CT scans can evaluate drug retention and tumor response over time.vi. Pain Management:a. NSAIDs or mild analgesics to alleviate post-procedural discomfort. vii. Wound Care:a. Sterile dressings and site monitoring for any signs of infection.

[0136] Intratumoral drug delivery in breast cancer using a thin catheter with a needle offers a targeted, minimally invasive treatment that maximizes local drug efficacy while reducing systemic side effects. The use of imaging guidance, controlled injection rates, and precision placement techniques ensures optimal drug distribution within the tumor, enhancing therapeutic outcomes with minimal complications.EXAMPLE 27 - Technical Specifications for Using a Syringe to Deliver a Drug Intratumorally in Breast Cancer.

[0137] Intratumoral drug delivery using a syringe is a localized and minimally invasive approach for treating breast cancer. This method enhances drug concentration within the tumor, reducing systemic toxicity while maximizing therapeutic effects. Given the heterogeneous nature of breast tumors, the choice of syringe, needle size, injection technique, and imaging guidance is crucial for effective drug delivery.1. Syringe and Needle Systemiv. Syringe Specifications:a. Capacity: 1 mL - 10 mL, depending on tumor size and drug volume required. b. Material: Sterile, disposable plastic or glass syringes for precise administration. c. Plunger Control: Smooth movement to allow controlled injection without excessive force.v. Needle Specifications:a. Gauge: 18G-25G, selected based on the tumor’s consistency and vascularity. b. Length: 10-25 mm, depending on tumor depth and patient anatomy.c. Tip Design: Short bevel or blunt-tip to prevent deep penetration and tissue rupture.vi. Injection Volume:a. Small tumors (<1 cm): 0.5—1 mL per site.b. Medium tumors (1-3 cm): 1-3 mL per site.c. Large tumors (>3 cm): Multi-site injections with total volume up to 10 mL. vii. Injection Speed:a. Flow rate: 0.1-1.0 mL per minute to ensure optimal drug diffusion while preventing tissue rupture.. Imaging and Guidance for Needle Placementv. Ultrasound-Guided Injection (Preferred for Accurate Targeting):a. Provides real-time visualization of the tumor and surrounding breast tissue. b. Helps avoid major blood vessels, lymphatics, and ducts.vi. Manual Palpation and Clinical Assessment (For Superficial or Easily Identifiable Tumors):a. Used in clinically palpable breast tumors, ensuring direct needle insertion at the tumor center.vii. MRI or CT Guidance (For Deep-Seated or Dense Breast Tissue Tumors):a. Useful for non-palpable or fibroglandular tumors requiring precision in needle placement.. Procedural Stepsv. Patient Preparation:a. Local anesthesia (lidocaine or bupivacaine) to numb the injection site. b. Patient positioned supine with arm raised (for upper outer quadrant tumors) or in an adjusted position based on tumor location.vi. Tumor Localization and Needle Insertion:a. Ultrasound or manual palpation to confirm tumor margins.b. Needle inserted at an angle of 30°-45° to ensure proper penetration into tumor mass.vii. Drug Injection:a. Slow, controlled injection (0.1-1.0 mL per minute) to prevent drug leakage and tissue rupture.b. Multi-point injections may be required for large or irregularly shaped tumors to enhance coverage.viii. Needle Withdrawal and Post-Injection Monitoring:a. Needle is slowly retracted while applying slight pressure to prevent leakage. b. Injection site is monitored for swelling, bleeding, or unexpected drug diffusion.4. Safety Considerationsiv. Avoiding Drug Leakage and Swelling:a. Slow injection rates and precise needle depth ensure optimal drug retention within the tumor.v. Avoiding Major Blood Vessels and Lymph Nodes:a. Ultrasound guidance ensures accurate placement away from critical structures. vi. Preventing Breast Tissue Damage and Necrosis:a. The use of fine-gauge needles (18G-25G) and controlled drug dispersion minimizes local tissue trauma.vii. Complication Management:a. Preparedness for bruising, hematoma, infection, or local necrosis, particularly in highly vascularized breast tissue.5. Post-Procedure Careiv. Observation:a. Monitor for swelling, pain, or hematoma formation at the injection site.v. Follow-Up Imaging:a. Ultrasound, MRI, or mammography may be performed postinjection to confirm drug distribution and tumor response. vi. Pain Management:a. NSAIDs or mild analgesics to alleviate discomfort.vii. Compression and Dressing:a. A light compression bandage may be applied to minimize bruising and swelling.

[0138] Using a syringe for intratumoral drug delivery in breast cancer is a precise, minimally invasive method that allows for targeted treatment while minimizing systemic side effects. The use of ultrasound guidance, fine-gauge needles, and controlled injection rates ensures effective drug delivery while reducing complications. This approach is particularly beneficial for localized, non- resectable tumors or as an adjunct to other treatments such as chemotherapy and immunotherapy.REFERENCESLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-l. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3-25. 1. Advanced Drug Delivery Reviews, 46(1-3), 3-26. https: / / doi.org / 10.1016 / S0169-409X(00)00129-0 Usama, S. M., Lin, C.-M., & Burgess, K. (2018). On the Mechanisms of Uptake of Tumor-Seeking Cyanine Dyes. Bioconjugate Chemistry, 29(11), 3886-3895. https: / / doi.org / 10.1021 / acs.bioconjchem.8b00708Wangngae, S., Chansaenpak, K., Weeranantanapan, O., Piyanuch, P, Sumphanapai, T, Yamabhai, M., Noisa, P., Lai, R.-Y, & Kamkaew, A. (2022). Effect of morpholine and charge distribution of cyanine dyes on cell internalization and cytotoxicity. Scientific Reports, 12(f), 4173. https: / / doi.org / 10.1038 / s41598-022-07533-5

Claims

AMENDED CLAIMSreceived by the International Bureau on 23 September 2026 (23.09.2026)1. (Replaces claim 1 as filed) A method of eliminating a tumor in a subject comprising:A) Contacting the tumor with a compound, wherein the compound is capable of being totally or partially selectively retained in the tumor;B) administering the compound locally in the tumor through a medical device, wherein the compound is delivered intratumorally under controlled and optimized conditions of injected dose, flow rate, volume and fluid pressure to prevent tumor rupture, and maximize compound retention in the tumor and minimize leakage of the compound; andC) wherein the compound is capable of causing total or partial tumor elimination.

2. (Canceled)3. (Unchanged) The method of claim 1, wherein the method minimizes secondary toxicity effects of the compound.

4. (Unchanged) The method of claim 1 , wherein the tumor is selected from a group consisting of pancreatic cancer, head and neck cancer, bladder cancer, lung cancer, liver cancer, ovarian cancer, colorectal cancer, cervical cancer, thyroid cancer, oral cancer, melanoma, brain tumors, kidney cancer, prostate cancer, throat cancer, stomach cancer, and breast cancer.

5. (Unchanged) The method of claim 4, wherein the tumor is pancreatic cancer.

6. (Replaces claim 6 as filed) The method of claim 1, wherein the medical device is selected from a group consisting of a catheter with a needle tip, a syringe, a microcatheter, a miniaturized robotic mechanism, and a robotic drug-releasing device.

7. (Unchanged) The method of claim 1, wherein the compound has at least one or more of the following chemical or physical properties:A) is retained selectively within the tumor,B) has poor systemic circulation in the bloodstream,C) has poor systemic diffusion in the body,D) has low solubility in water,E) has a high binding capacity to the tumor’s molecular components,F) has a low binding preference for the plasma components and higher binding to tissues including tumors,G) has low oral absorption, orH) or a combination of any of the above factors.

8. (Replaces claim 8 as filed) The method of claim 7, wherein the compound is selected from a group consisting of 3-(6-((6-ammoniohexyl)amino)-6-oxohexyl)-l,l-dimethyl-2-((E)-2- ((E)-3 -((E)-2-( 1 , 1 ,3 -trimethyl- 1 ,3 -dihydro-2H-benzo [e] indol-2- ylidene)ethylidene)cyclohex- 1 -en- 1 -yl)vinyl)- 1 H-benzo[e] indol-3 -ium, Tivantinib (ARQ 197), Irinotecan, Sorafenib, Sorafenib Analog XL999, BAY 43-9006 (Preclinical Sorafenib Derivative), Paclitaxel (Taxol), Venetoclax (Venclexta), Vismodegib (Erivedge), Dasatinib (Spry cel), Epothilones A and B (Natural Epothilones), Bryostatin-1, Flavopiridol (Alvocidib), Tanespimycin (17-AAG), XL184 (Preclinical Cabozantinib Analog), PR-104, LY293111, DMXAA (Vadimezan), Marizomib (NPI-0052), Epothilone B Derivatives, Obatoclax, Bexarotene Analog (RXR Agonist), SNS-032, IPI-504 (Retaspimycin), XL281, GRN163L (Imetelstat Precursor), Acridine orange 10-nonyl (NAO), methylene blue, 1,9-dimethyl methylene blue, benzalkonium chloride, crystal violet, rhodamine, rhodamine 800, basic red 5 dye, basic blue 1 dye, nile red dye, rosamine-based dyes, mitotracker red dye, and aminocyanine.

9. (Replaces claim 9 as filed) The method of claim 6, wherein a laparoscope, an endoscope, or a stereotactic system is used for assisting in intratumoral injection.

10. (Canceled)11. (Replaces claim 11 as filed) The method of claim 9, wherein there is at least one port for catheter insertion through the laparoscope, the endoscope, or the stereotactic system.12-17. (Canceled)18. (Replaces claim 18 as filed) The method of claim 6, wherein the catheter is connected to an automated syringe pump or a manual injection system.

19. (Replaces claim 19 as filed) The method of claim 18, wherein the flow rate of the automated syringe pump or the manual injection system is between about 0.1 mL per minute and about 0.5 mL per minute.

20. (Unchanged) The method of claim 1, wherein intratumoral pressure is measured in realtime.

21. (Unchanged) The method of claim 5, wherein the compound is 3-(6-((6- ammoniohexyl)amino)-6-oxohexyl)- 1 , 1 -dimethyl-2-((E)-2-((E)-3-((E)-2-(l , 1,3- trimethyl-l,3-dihydro-2H-benzo[e]indol-2-ylidene)ethylidene)cyclohex-l-en-l-yl)vinyl)- lH-benzo[e]indol-3-ium, a laparoscope is used, there are at least three laparoscopic ports, the medical device is a catheter with a needle tip, at least one catheter port, the tumor is illuminated, carbon dioxide is used to maintain a pneumoperitoneum pressure of about 10 mmHg to about 15 mmHg, the catheter has an outer diameter of one to two mm, a length of about 20 cm to about 30 cm, and is made of a biocompatible polymer, the needle tip is an about 18Gto about 22G Gauge, the needle tip has a length of about 10 mm to 15 mm, and the needle tip has an angled bevel, and the catheter is connected to a syringe pump or manual injection system with a flow rate between about 0.1 mL per minute and about 0.5 mL per minute.

22. (Canceled)23. (Canceled)24. (Unchanged) The method of claim 1, wherein the compound is photodynamic, photothermal, photomechanical, photoimmunotherapy, activated photochemotherapy, or a combination thereof.

25. (Unchanged) The method of claim 24, wherein the compound is exposed to electromagnetic radiation with a wavelength between about 650 nm and about 950 nm, with a wavelength between about 1000 nm and about 1350 nm, with a wavelength between about 1500 nm and about 1800 nm, or with a wavelength between about 2100 nm and about 2300 nm.

26. (Unchanged) The method of claim 1, wherein the subject is a human patient, a laboratory rodent, a farm animal, a livestock animal, or a domestic animal.27-280. (Canceled)281. (Unchanged) A method of eliminating tumors in a subject comprising:A) Contacting a first tumor with a compound, wherein the compound is capable of being totally or partially selectively retained in the first tumor;B) administering the compound locally in the first tumor through a medical device, wherein the compound is delivered intratumorally under controlled conditions; andC) wherein the compound causes total or partial elimination of a second tumor which was not administered the compound.

282. (New) The method of claim 1, wherein the compound has an injected dose of concentration in the range of 1 pM to 1000 mM with an injected volume in the range of 0.001 mL to 0.5 mb per cm3of tumor. Preferably, a high concentration of 7 mM or higher and an injected volume from 0.1 to 0.2 mL per each cm3of tumor.

283. (New) The method of claim 1, wherein the compound is administered to the tumor at a flow rate in the range of 0.001 mL per minute to 2.0 mL per minute. Preferably between 0.1 to 0.5 mL per minute.

284. (New) The method of claim 1, wherein the compound is administered to the tumor while the intratumoral fluid pressure does not exceed the rupture pressure in the range of about 150 mmHg to about 200 mmHg.